

Binding to an Unusual Inactive Kinase Conformation by Highly Selective Inhibitors of Inositol-Requiring Enzyme 1 α Kinase-Endoribonuclease

Giampiero Colombano,[†] John J. Caldwell,[†] Thomas P. Matthews,[†] Chitra Bhatia,[§] Amar Joshi,[§] Tatiana McHardy,[†] Ngai Yi Mok,[†] Yvette Newbatt,[†] Lisa Pickard,[†] Jade Strover,[‡] Somaieh Hedayat,[†] Michael I. Walton,[†] Stephanie M. Myers,[†] Alan M. Jones,[†] Harry Saville,[†] Craig McAndrew,[†] Rosemary Burke,[†] Suzanne A. Eccles,[†] Faith E. Davies,^{‡,⊥} Richard Bayliss,^{§,||} and Ian Collins^{*,†,⊥}


[†]Cancer Research UK Cancer Therapeutics Unit and [‡]Division of Molecular Pathology, The Institute of Cancer Research, London SW7 3RP, U.K.

[§]Department of Molecular and Cell Biology, University of Leicester, Leicester LE1 7RH, U.K.

^{||}School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds LS2 9JT, U.K.

Supporting Information

ABSTRACT: A series of imidazo[1,2-*b*]pyridazin-8-amine kinase inhibitors were discovered to allosterically inhibit the endoribonuclease function of the dual kinase-endoribonuclease inositol-requiring enzyme 1 α (IRE1 α), a key component of the unfolded protein response in mammalian cells and a potential drug target in multiple human diseases. Inhibitor optimization gave compounds with high kinome selectivity that prevented endoplasmic reticulum stress-induced IRE1 α oligomerization and phosphorylation, and inhibited endoribonuclease activity in human cells. X-ray crystallography showed the inhibitors to bind to a previously unreported and unusually disordered conformation of the IRE1 α kinase domain that would be incompatible with back-to-back dimerization of the IRE1 α protein and activation of the endoribonuclease function. These findings increase the repertoire of known IRE1 α protein conformations and can guide the discovery of highly selective ligands for the IRE1 α kinase site that allosterically inhibit the endoribonuclease.



INTRODUCTION

The dual kinase-endoribonuclease inositol-requiring enzyme 1 α (IRE1 α ; ERN1) is a central and conserved component of the unfolded protein response (UPR) activated by eukaryotic cells in reaction to endoplasmic reticulum (ER) stress, caused by an excess of misfolded proteins in the ER lumen.^{1,2} Activation of the UPR reduces protein translation and increases the protein-folding capacity. If this initial response does not alleviate ER stress, prolonged activation of the UPR signaling network leads to apoptosis. Thus, the balance of downstream anti- and proapoptotic signaling pathways activated by the UPR determines cell fate in the presence of acute or chronic proteotoxic stress.

IRE1 α is an ER membrane resident protein with serine/threonine kinase and endoribonuclease (RNase) functions contained in its cytosolic domain.³ The accumulation of unfolded or misfolded proteins in the ER lumen triggers oligomerization of IRE1 α and kinase autophosphorylation, resulting in activation of the RNase.^{4–6} The RNase specifically cleaves the messenger RNA (mRNA) coding for the unspliced transcription factor X-box protein 1 (XBP1u) to remove a 26 base pair intron, and subsequent ligation produces the mRNA of the active, spliced form (XBP1s) of the transcription factor.⁷

XBP1s-dependent transcription includes upregulation of ER-resident molecular chaperones required to relieve aberrant protein folding.⁸ In contrast, nonspecific cleavage of other mRNAs localized at the ER membrane by IRE1 α RNase (termed regulated IRE1-dependent decay) is proposed to exert an apoptotic effect.⁹ Additionally, the interaction of TRAF2 with oligomerized phospho-IRE1 α elicits signaling through the JNK/c-JUN axis, independent of IRE1 α RNase activity.¹⁰ In mammalian cells, IRE1 α functions with the transcriptional repression and regulation of apoptosis effected by the other UPR elements, ATF6 and PERK, to alleviate ER stress or to direct cell death.^{1,2}

Dysregulation of IRE1 α -XBP1s signaling is implicated in a number of human diseases, including cancer, diabetes, lipidemia, inflammatory disease, and neurodegeneration.^{1,11} Signaling through IRE1 α -XBP1s has been proposed as important for the survival of myeloma cells, as well as breast and prostate cancers.^{12–14} Recently, in an ovarian cancer in vivo model, XBP1s function has been shown to suppress proper presentation of tumor-associated antigens by tumor-

Received: November 4, 2018

Published: February 19, 2019

infiltrating dendritic cells, thus determining the degree of T-cell antitumor immune response and suggesting that modulation of XBP1 splicing in normal tissue may be an alternative approach for an anticancer therapy.¹⁵

There is a clear need for selective chemical tools to explore the consequences of IRE1 α inhibition by different mechanisms in cancer and nontransformed cells and to study the IRE1 α -XBP1s pathway in other human diseases. Given the diverse nature of IRE1 α signaling outputs, inhibitors targeting the kinase or RNase functions, or both, may have different consequences for cell fate, which may further vary according to cell context. Reversible covalent binders targeting the RNase active site directly have been reported from a salicylaldehyde scaffold^{16–18} and have been shown to inhibit cancer cell growth.^{18–20} The pharmacology of inhibitors binding at the IRE1 α kinase site is complicated by the possibility of allosteric inhibition or activation of the RNase function depending on the conformation of the kinase domain and oligomerization state that is stabilized.²¹ Allosteric inhibition of the RNase function has been associated with type II kinase site ligands that bind the DFG-out conformation of the kinase²¹ or other compounds that displace the α C-helix of the kinase from the active conformation.^{22–24} While a series of highly selective, kinase site binding, allosteric inhibitors of IRE1 α RNase have shown no direct cytotoxic effect on a range of cancer cell lines,²³ compounds with this profile remain of interest for other therapeutic approaches that target nonmalignant cells.²⁵ In contrast to type II and α C-helix displacing scaffolds, reported type I IRE1 α kinase site ligands promote dimerization and activate the RNase function.^{6,21} The identification of new activators and inhibitors of IRE1 α RNase and understanding the allosteric mechanisms linking the kinase and RNase sites are therefore of continued importance for the development of new therapeutics.

We previously described the type I imidazo[1,2-*b*]pyridazine kinase inhibitor **1** (Figure 1) that allosterically activates IRE1 α endoribonuclease *in vitro*.⁶ While screening chemical scaffolds based on **1**, we unexpectedly discovered the related type I imidazo[1,2-*b*]pyridazin-8-amine **2** (Figure 1A) to be an inhibitor of both the kinase and RNase functions of IRE1 α . In this study, we show how **2** and more potent analogues bind to a previously undescribed inactive conformation of monomeric IRE1 α involving major rearrangements of key secondary structure in the kinase domain, including disordering of the α C-helix and disruption of the hydrophobic spine of the protein, which together confer high IRE1 α kinase binding selectivity and inhibition of both kinase and RNase functions. We confirm that these allosteric modulators disrupt all downstream signaling through IRE1 α in human cells, thus validating targeting of this unusual binding mode as a new way to generate selective and cell active inhibitors of IRE1 α .

SYNTHETIC CHEMISTRY

We established short synthetic routes to prepare analogues of **2** using the differential reactivity of the polyhalogenated imidazo[1,2-*b*]pyridazine **3** (Scheme 1). Selective displacement of the 8-bromo substituent introduced (cyclopropylmethyl)amine and was followed by Suzuki reactions of the 3-bromo group of **4** to give compounds **5–12**. The 6-chloro substituent of **3** and **4** might be expected to undergo competing nucleophilic substitution or palladium insertion but proved notably stable under the conditions studied.²⁶ To replace the indazol-5-yl substituent of **2** with 2-





Figure 1. (A) Structures of the IRE1 α RNase activator **1** and the structurally related RNase inhibitor **2**. (B) Structures of selected published IRE1 α kinase-RNase inhibitors.

(*N*-phenyl)amino-1*H*-benzo[*d*]imidazole, the intermediate **13** was prepared from 5-bromo-2-chloro-1*H*-benzo[*d*]imidazole by displacement of the 2-chloro group with aniline and *N*-protection, before palladium-catalyzed installation of the boronate (Scheme 1). Compound **13** was obtained and used as a mixture of *N*-Boc 2-aminobenzimidazole regioisomers, with complete *N*-deprotection observed in the subsequent Suzuki reaction. 2-(Methylamino)benzimidazole **14** did not require *N*-protection for successful reaction. Other *N*-methylated 2-aminobenzimidazoles **16** and **18** were synthesized from the nitrophenyl boronates **15** and **17**, respectively, by nitro group reduction and condensation with isothiocyanatobenzene.²⁷

The synthesis was adapted to vary the 8-amino substituent of the imidazo[1,2-*b*]pyridazine by reacting a range of amines with substrate **3** to give **19–21** and **27–29** (Scheme 2). For the unsubstituted 1,4-diaminocyclohexanes **22** and **23**, *N*-protection of the terminal amine, to ensure selectivity, and higher temperatures were required in the nucleophilic substitution step. The more elaborate 1,4-diaminocyclohexane substituents incorporated into **24–26** were made prior to reaction with **3**. Fluorine substituents were introduced into the 2-(*N*-phenyl)amino-1*H*-benzo[*d*]imidazole group starting from the appropriate fluorinated 4-bromobenzene-1,2-diamines via condensation with isothiocyanatobenzene, and the route was telescoped to generate compounds **30–32**.

RESULTS

Compound **2** (Figure 1A and Table 1) was discovered through screening of type I kinase scaffolds related to the IRE1 α kinase inhibitor-RNase activator **1**.⁶ Unexpectedly, we determined that while inhibiting the kinase activity with similar potency to **1**, compound **2** was an inhibitor of the RNase function *in vitro*,

Scheme 1. Syntheses of Compounds 2–18^a

^aReagents and conditions: (i) 2-chloroacetaldehyde, EtOH, 50 °C, 21 h, 78%; (ii) *N*-bromosuccinimide, CH₂Cl₂, 0 °C to room temperature (rt), 16 h, 84%; (iii) cyclopropylmethanamine, tetrahydrofuran (THF), rt, 3 h, 93%; (iv) heteroaryl boronate, Pd(OAc)₂, 1,1'-bis(*di-tert*-butylphosphino)ferrocene, 2 M Na₂CO₃, dioxane, 120–135 °C, 15–22 h, 5–51%; (v) (a) PhNH₂, 180 °C (microwave), 1 h; (b) (Boc)₂O, 4-dimethylaminopyridine (DMAP), THF, rt, 16 h; (c) bis(pinacolato)diboron, KOAc, Pd(dppf)Cl₂·CH₂Cl₂, 1,4-dioxane, 100 °C, 16 h, 53% over three steps; (vi) PhNMe, 180 °C (microwave), 1 h, 86%; (vii) bis(pinacolato)diboron, KOAc, Pd(dppf)Cl₂·CH₂Cl₂, 1,4-dioxane, 100 °C, 16 h, 36%; (viii) isothiocyanatobenzene, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC), THF, 50 °C, 5 h, 17–45%.


suggesting a different allosteric effect on the RNase compared to typical type I IRE1 α kinase inhibitors.²¹ The small size of **2** compared to reported IRE1 α kinase-RNase inhibitors from type II- or type I-extended scaffolds (e.g., KIRA3 and compound **16**, respectively; Figure 1B) was also attractive as a potential starting point for inhibitor optimization.^{21,23,24} We hypothesized that the orientation of **2** within the IRE1 α adenosine 5'-triphosphate (ATP) site would be similar to that determined for **1** (PDB 4Z7H).⁶ We anticipated that the key hinge-binding hydrogen bond from N-1 of the imidazo[1,2-*b*]pyridazine would be maintained and that a new hydrogen bond could be formed to the hinge region from the 8-amino group, replacing the CH \cdots O interaction seen for **1**. In this orientation, the indazole substituent would be directed toward the α C-helix, taking the place of the benzamide moiety in **1**, while the cyclopropylmethyl group would be directed out toward solvent. The imidazo[1,2-*b*]pyridazin-8-amine hinge-binding group has recently been shown to adopt such a binding mode to the kinase, monopolar spindle 1 (MPS1).^{28,29}

We used *in vitro* biochemical assays to measure compound binding and effects on IRE1 α autophosphorylation and endoribonuclease activities, to investigate the structure–activity relationships around **2** and test the proposed binding model. Recombinant IRE1 α protein corresponding to the cytoplasmic kinase-endoribonuclease extended (KEN) domain (G547 IRE1 α) was produced separately in phosphorylated and dephosphorylated states, as confirmed by intact protein mass spectrometry (MS) (Figure S1).³⁰ We used our previously described DELFIA format to determine the inhibition of recombinant IRE1 α S274 autophosphorylation.³¹ To measure compound binding to IRE1 α , we developed a LanthaScreen Eu

Kinase binding FRET assay, which monitored the displacement of an ATP-site tracer. To determine the allosteric effect of the kinase inhibitors on IRE1 α RNase activity, we used a FRET-based assay to measure the cleavage of a short stem-loop RNA sequence derived from the endogenous cleavage site in XBP1u mRNA (Figure S2).^{21,30}

We initially investigated the role of the indazol-5-yl substituent in **2** (Table 1). The availability and correct positioning of hydrogen bond donor/acceptor functionality was critical, with neither the *N*-methyl (**5**) nor regioisomeric (**6**) analogues showing activity. Only weak inhibition of IRE1 α autophosphorylation in the sensitive DELFIA format was observed for the indol-5-yl derivative (**7**). The benzimidazol-5-yl analogue (**8**) also inhibited IRE1 α autophosphorylation but showed significantly weaker ATP-site binding in the LanthaScreen assay and no RNase inhibition. For the RNase assay, this may in part reflect the reduced potency of **8** compared to **2**. The weak potency for ATP-site binding assay was unexpected, but based on the promising inhibition of IRE1 α autophosphorylation, we pursued further substitution of the benzimidazol-5-yl scaffold.

We assumed that the indazol-5-yl substituent of **2** potentially interacted with the same region of the IRE1 α active site as the benzamide of **1**, in particular with residues such as D711 from the DFG motif or K599. Compound **1** also interacted with a water molecule that was in contact with E612 from the α C-helix.⁶ Therefore, we investigated 2-(*N*-phenyl)amino substitution of the benzimidazole **8**. The 2-(*N*-phenyl)-aminobenzimidazole motif is a known isostere for the diaryl urea motif more commonly found in type II kinase inhibitors, as it is capable of mimicking the hydrogen-bonding pattern

Scheme 2. Syntheses of Compounds 19–32^a

^aReagents and conditions: (i) amine, THF, rt, 16 h, 60–97%; (ii) heteroaryl boronate, Pd(OAc)₂, 1,1'-bis(di-*tert*-butylphosphino)ferrocene, 2 M Na₂CO₃, 1,4-dioxane, 130 °C, 16 h, 4–55%; (iii) *tert*-butyl ((1*r*,4*r*)-4-aminocyclohexyl)carbamate, THF, 50 °C, 16 h, quantitative; (iv) HCl, 1,4-dioxane, rt, 2 h, 99%; (v) (a) LiAlH₄, THF, 0 °C to reflux, 4 h; (b) ethyl 1,3-dioxoisindoline-2-carboxylate, Et₃N, CH₂Cl₂, rt, 15 h; (c) 3, Et₃N, 1,4-dioxane–dimethyl sulfoxide (DMSO), 100 °C, 22 h, 52% over three steps; (vi) 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1*H*-indazole, Pd(OAc)₂, 1,1'-bis(di-*tert*-butylphosphino)-ferrocene, 2 M Na₂CO₃, 1,4-dioxane, 130 °C, 21 h, then NH₂NH₂·H₂O, 100 °C, 48 h, 34%; (vii) amine, THF, 50 °C, 16 h, 29–85%; (viii) (a) *tert*-butyl ((1*r*,4*r*)-4-aminocyclohexyl)carbamate, Et₃N, CH₂Cl₂, rt, 20 h; (b) HCl–1,4-dioxane, MeOH, rt, 2 h, 37% over two steps; (ix) 3, Et₃N, 1,4-dioxane–DMSO, 50 °C, 23 h, 58%; (x) (a) isothiocyanatobenzene, EDC, THF, 50 °C, 5 h; (b) (Boc)₂O, DMAP, THF, rt, 16 h; (c) bis(pinacolato)diboron, KOAc, Pd(dppf)Cl₂·CH₂Cl₂, 1,4-dioxane, 135 °C, 24 h; (d) 3-bromo-6-chloro-*N*-((1-methylpiperidin-4-yl)methyl)imidazo[1,2-*b*]pyridazin-8-amine, Pd(OAc)₂, 1,1'-bis(di-*tert*-butylphosphino)-ferrocene, 2 M Na₂CO₃, 1,4-dioxane, 135 °C, 16 h, 2–5% over four steps.

made by type II urea inhibitors in the inactive DFG-out conformation of the kinase domain.³² The addition of aryl urea groups or their isosteres to convert type I kinase inhibitor scaffolds to type II molecules is a well-established approach.³³ Gratifyingly, we observed that the 2-(*N*-phenyl)-aminobenzimidazole **9** had similar kinase site binding affinity to **2**, and improved on the inhibition of IRE1α RNase activity. Consistent with a role for the 2-(*N*-phenyl)aminoimidazole functionality in forming multiple hydrogen bonds, *N*-

methylation at any position reduced inhibitory activity (see **10–12**).

With two variations of the imidazo[1,2-*b*]pyridazin-8-amine core identified that led to RNase inhibition, the effects of varying the 8-amino group on potency and physicochemical properties were studied. The aqueous (aq) buffer solubilities of **2** (*K*_{Sol} = 0.8 μM) and **9** (*K*_{Sol} = 2.9 μM) were low, consistent with their measured lipophilicities (**2**, Log *D*_{7.4} = 3.4; **9**, Log *D*_{7.4} = 4.1). We therefore sought to introduce polar or ionizable groups to improve solubility and hypothesized that

Table 1. In Vitro Binding and Inhibition of IRE1 α Kinase and RNase Activities by 2, 5–12

no.	IRE1 α S724 autophosphorylation IC ₅₀ (μ M) ^a	IRE1 α ATP-site binding IC ₅₀ (μ M) ^b	IRE1 α RNase activity IC ₅₀ (μ M) ^c
1 ^e	0.218 (\pm 0.15) ⁶	1.18 (\pm 0.17)	activator EC ₅₀ 0.143 ⁶
2	0.303 (\pm 0.15)	1.60 (\pm 0.91)	8.90 (\pm 0.21)
5	>10	>10	n.d. ^d
6	>10	>10	n.d.
7	4.06 (\pm 0.74)	>10	>10
8	0.89 (\pm 0.14)	46% @10 μ M ^e	>10
9	0.81 (\pm 0.4)	0.84 (\pm 0.42)	2.67 (\pm 1.89)
10	>10	>10	n.d.
11	>10	>10	n.d.
12	2.7 (\pm 1.1)	>10	n.d.

^aInhibition of recombinant G547 IRE1 α kinase-endoribonuclease extended (KEN) domain pS274 autophosphorylation measured in dissociation-enhanced lanthanide fluorescence immunoassay (DELFLIA) format, mean (\pm standard deviation (SD)) for $n \geq 3$. ^bInhibition of ATP-site LanthaScreen tracer binding to recombinant dephosphorylated G547 IRE1 α KEN domain, mean (\pm SD) for $n \geq 3$. ^cInhibition of G547 IRE1 α -dependent cleavage of a fluorescence resonance energy transfer (FRET)-labeled stem-loop RNA containing the XBP1 cleavage site, mean (\pm SD) for $n \geq 3$. ^dn.d. = not determined. ^e \pm 4%, $n = 4$.

the vector defined by the cyclopropylmethyl group should be directed toward solvent. Importantly, studies leading to the IRE1 α inhibitor compound **16** (Figure 1B) found that appending cyclic amine or cyclohexylamine substituents directed out of the ATP-binding pocket was essential for achieving high potency.²³ Our presumed binding mode of the core scaffolds **2** and **9** oriented the 8-amino substituent in a similar direction. We investigated a range of substituents, including cyclic amines analogous to those described in the development of compound **16**, with selected examples highlighted in Table 2.

Introduction of polar groups generally maintained the dual kinase-RNase inhibitory profile of the compounds while enhancing potency. Thus, replacement of the cyclopropylmethyl substituent by tetrahydropyran-4-yl resulted in submicromolar inhibitors of IRE1 α RNase function, **19** and **27**. Aqueous solubility remained low (**19**, $K_{\text{Sol}} = 2.2 \mu\text{M}$; **27**, $K_{\text{Sol}} = 2.4 \mu\text{M}$), but was increased in the basic *N*-methylpiperidin-4-yl derivatives **20** ($K_{\text{Sol}} = 58 \mu\text{M}$, $\text{Log } D_{7.4} = 1.8$) and **28** ($K_{\text{Sol}} = 41 \mu\text{M}$, $\text{Log } D_{7.4} = 2.7$), which also showed improvements in RNase inhibition.

For the 3-(indazol-5-yl) substituted analogues, extension of the piperidine substituent had a negligible effect on compound affinity or potency (see **21**). However, the *trans*-1,4-diaminocyclohexane analogue **22** showed enhanced binding and RNase inhibition. Notably, *N*-8-methylation to give **23** led to loss of activity, consistent with the assumed kinase hinge-binding role of the 8-amino substituent. Further substitution of the *trans*-1,4-diaminocyclohexane group was tolerated, exemplified by **24–26**, and led to potent in vitro inhibitors of IRE1 α RNase activity with acceptable aqueous solubility (e.g., **26**, $K_{\text{Sol}} = 80 \mu\text{M}$, $\text{Log } D_{7.4} = 1.8$).

For the 3-(2-(*N*-phenyl)aminobenzimidazol-5-yl) substituted compounds, the (*N*-methylpiperidin-4-yl)methyl analogue **29** provided an enhancement in binding and RNase inhibitory potency without the need for further substitution. We examined fluorination of the benzimidazole group but

Table 2. In Vitro Binding and Inhibition of IRE1 α Kinase and RNase Activities by 19–32 and Published Compound KIRA3

no.	IRE1 α S724 autophosphorylation IC ₅₀ (μ M) ^a	IRE1 α ATP-site binding IC ₅₀ (μ M) ^b	IRE1 α RNase activity IC ₅₀ (μ M) ^c
19	0.19 (\pm 0.11)	0.25 (\pm 0.07)	0.48 (\pm 0.19)
20	0.77 (\pm 0.13) ^d	0.83 (\pm 0.19)	0.13 ^e
21	0.47 (\pm 0.09)	0.87 (\pm 0.24)	0.16 ^e
22	0.32 (\pm 0.09)	0.11 (\pm 0.04)	0.072 (\pm 0.011)
23	>10	>10	n.d. ^f
24	0.15 (\pm 0.05)	0.14 (\pm 0.02)	0.033 ^e
25	0.19 (\pm 0.01) ^d	0.11 (\pm 0.01)	0.122 (\pm 0.026)
26	0.24 (\pm 0.09)	0.087 (\pm 0.022)	0.027 (\pm 0.007)
27	0.20 (\pm 0.05)	2.0 (\pm 0.94)	0.51 ^e
28	0.13 (\pm 0.06)	0.67 (\pm 0.23)	0.18 ^e
29	0.13 (\pm 0.03)	0.39 (\pm 0.11)	0.09 (\pm 0.05)
30	0.15 (\pm 0.02)	0.33 (\pm 0.04)	0.10 (\pm 0.05)
31	0.16 (\pm 0.06)	0.27 (\pm 0.17)	0.08 (\pm 0.05)
32	0.16 (\pm 0.05)	0.48 (\pm 0.05)	0.17 (\pm 0.09)
KIRA3	0.29 (\pm 0.06)	0.40 (\pm 0.16)	0.45 (\pm 0.10)

^aInhibition of recombinant G547 IRE1 α KEN domain pS274 autophosphorylation measured in DELFLIA format, mean (\pm SD) for $n \geq 3$. ^bInhibition of ATP-site LanthaScreen tracer binding to recombinant dephosphorylated G547 IRE1 α KEN, mean (\pm SD) for $n \geq 3$. ^cInhibition of G547 IRE1 α -dependent cleavage of a FRET-labeled stem-loop RNA containing the XBP1 cleavage site, mean (\pm SD) for $n \geq 3$. ^d $n = 2$. ^eSingle determination. ^fn.d. = not determined.

found only marginal (<2-fold) gains in affinity and potency (see **30–32**). The most potent RNase inhibitor **31** from this scaffold showed moderate solubility ($K_{\text{Sol}} = 38 \mu\text{M}$), reflecting the high lipophilicity ($\text{Log } D_{7.4} = 3.7$).

Cellular inhibition of IRE1 α RNase function was measured for selected compounds using a bioluminescent reporter assay in HEK293 cells stably expressing an XBP1 luciferase fusion mRNA to quantify XBP1 mRNA splicing (Table 3). In the

Table 3. Cellular Activities of Selected IRE1 α Inhibitors

no.	XBP1 luciferase fusion mRNA splicing in HEK293 cells IC ₅₀ (μ M) ^a	cytotoxicity in HEK293 reporter cells EC ₅₀ (μ M) ^b
2	4.2 (\pm 1.7)	>49
22	2.9 (\pm 0.87)	28 (\pm 6.9)
26	1.12 (\pm 0.24)	>49
29	0.89 (\pm 0.1)	12 ^c
31	0.71 (\pm 0.33)	9.0 (\pm 1.6)
KIRA3	0.76 ^c	>49

^aInhibition of tunicamycin-induced IRE1 α -dependent splicing of an XBP1u-luciferase mRNA reporter stably expressed in HEK293 cells, mean (\pm SD) for $n \geq 2$. ^bCytotoxicity in HEK293 cells stably expressing an XBP1u-luciferase mRNA reporter, measured using the Alamar Blue format, mean (\pm SD) for $n \geq 2$. ^cSingle determination.

absence of ER stress, translation of the XBP1u mRNA terminates before the luciferase sequence, while exogenous induction of ER stress leads to IRE1 α -dependent XBP1 mRNA splicing and results in tandem translation of the XBP1s-luciferase reporter protein. The imidazo[1,2-*b*]pyridazine **2** moderately inhibited tunicamycin-induced mRNA splicing. Enhancement of the in vitro potency and aqueous solubility of the scaffold, to give **22** and **26**, was accompanied by increased




Figure 2. Binding profiles of compounds **2**, **26**, and **31** tested at 1 μM concentrations of inhibitors against 455 wild-type and mutant human protein and lipid kinases (KINOMEScan, Eurofins) (see Table S1). Kinases where probe binding was inhibited by >90% at 1 μM test compound concentration are listed.

cellular activity. Likewise, the most potent and soluble 3-(2-(*N*-phenyl)aminobenzimidazol-5-yl) substituted analogues **29** and **31** gave submicromolar inhibitors of IRE1 α activity in cells. The optimization of in vitro potency in this series involved addition of basic groups, which may have impaired cell permeability and countered gains in potency for some of the more basic molecules. The cytotoxicity of compounds in the cell line was monitored to preclude interference in the assay, and no compound showed high cytotoxicity in the HEK293 cell line over the duration of the assay.

Compounds **2**, **26**, and **31** were profiled for broad kinase selectivity, as determined by inhibition of probe binding to recombinant human protein and lipid kinase domains at a concentration of 1 μM (KINOMEScan, Eurofins; Figure 2 and Table S1). Compound **2** gave >70% inhibition of 26/455 wild-type and mutant kinases tested. A distinct selectivity pattern was seen, with specific CMGC (CLK1, CLK2, CLK4, DYRK1A, DYRK1B, HIPK4) and TK (FLT3 wild type and mutants, KIT wild type and mutants, PDGFRB) subfamily members showing particularly high inhibition (>90%). The more potent derivative **26** maintained a very similar selectivity pattern, with additional kinases in the CMGC (DYRK2, HIPK1, HIPK2, HIPK3) and TK (PDGFRA) subfamilies related to those inhibited by **2** showing potent (>90%) inhibition. Overall, 54/455 wild-type and mutant kinases tested showed >70% inhibition, consistent with the increased potency of **26**. In contrast, the 2-(*N*-phenyl)-aminobenzimidazole **31** had a different selectivity pattern and very high selectivity with >70% inhibition of only 4/455 kinases. While two of the CMGC kinases inhibited by **2** and **26** (CLK1 and CLK4) were inhibited to a lesser extent by **31**, the most potently inhibited kinase was another CGMC family

member PCTK2 (97% inhibition at 1 μM test concentration). Interaction with wild-type and mutant TK subfamily kinases was minimal for **31**. The inhibitors **26** and **31** were, respectively, 9- and 100-fold selective for IRE1 α over the IRE1 β isoform, which has 80% sequence identity in the kinase domain,³⁴ in parallel LanthaScreen binding assays (Figure S3).

To better understand the origins of the potency and high selectivity of the inhibitors, we determined the X-ray structure of **2** bound to the cytosolic kinase-endoribonuclease (KEN) domain of IRE1 α (PDB 6HX1; Figure 3A,B). The complex 2-IRE1 α crystallized as a monomer in the unit cell. The kinase domain adopted an unusual conformation in which the α C-helix was remarkably disordered such that electron density was not modeled for most of this important secondary structural component. The DFG motif occupied an intermediate position between the canonical DFG-in and DFG-out conformations, which we term “DFG-up” for convenience. Thus, F712 was displaced from the “in” position that characterizes the active conformation of the regulatory hydrophobic spine of the kinase. A related intermediate conformation of the DFG motif has been observed in complexes of ligands bound to mutated Aurora A kinases.^{35,36} In the current structure, the residue Y628, also part of the hydrophobic spine in IRE1 α , was directed down toward the DFG motif, forming hydrogen bonds to D711 (2.7 Å) and the bound ligand. This contrasted with the upward orientation of Y628 seen when the regulatory spine is intact and the IRE1 α kinase domain is in the active conformation.⁶ The DFG-up, Y628-down conformation of 2-IRE1 α was accompanied by an unusual folding of the activation loop in an antiparallel double β -strand across the face of the ATP site, forming a region of β -sheet with the P-loop that enclosed the bound ligand. The residue H723 in the




Figure 3. Characterization of IRE1 α inhibitor binding modes. (A) Part of the crystal structure (PDB 6HX1) of **2** (green sticks) bound to IRE1 α KEN domain (gray image) showing the conformations of the DFG motif (cyan), activation loop segment (pale cyan), Y628 (blue), K599 (gray), and the observed part of the α C-helix (red). (B) Binding of **2** (green sticks) in the IRE1 α ATP site (gray sticks) with key residues labeled. Hydrogen bonds are shown as black dotted lines and selected water molecules as red spheres. (C) Details of the interactions of **2** (green sticks) with the DFG motif and Y628 in the IRE1 ATP site (gray image) with key residues labeled. Hydrogen bonds are shown as black dotted lines and selected water molecules as red spheres. (D) Comparison of **2** (purple), **1** (blue; PDB 4Z7H), Compound **16** (light blue; PDB 4U6R), and

Figure 3. continued

GSK2850163 (red; PDB 4YZ9) binding to IRE1 α KEN domain. Structures are overlaid on the hinge region (E643-L644-C645; lines), and the α C-helix (L602-S619; cartoon) is shown in the three structures in which it is present. (E) Schematic overlay showing the relationship between the DFG-out, DFG-up, and DFG-in conformations and the corresponding orientations of the observed activation loop segments (L714-S729) for GSK2850163-IRE1 α (red), 2-IRE1 (purple), compound 16-IRE1 α (light blue), and 1-IRE1 α (blue). (F) Comparison of components of the N-terminal kinase domain dimerization interface for the DFG-in, active conformation of 1-IRE1 α (blue and blue-white protomers) and DFG-up, and inactive conformation of 2-IRE1 α (purple). Structures are aligned on the kinase C-lobe (shown) and endonuclease C-terminal domain (not shown). Bound ligands are rendered as sticks; (G) model of **9** (green sticks) bound to IRE1 (gray image) based on the conformation observed for 2-IRE1. Predicted hydrogen bonds are shown as black dotted lines. (H) Detail showing the movement of Y628 as positioned in 2-IRE1 (gray image) required to accommodate the modeled binding of **9** (green sticks).

activation loop appeared to anchor this folding, with direct hydrogen bonding to E651 (2.8 Å) in the kinase domain C-terminus and a water-mediated hydrogen bond observed between H723 and L577 in the P-loop. Folding of the activation loop across the active site is an autoinhibitory mechanism for some kinases. For example, structures of imidazo[1,2-*b*]pyridazines and other ligands bound to the kinase MPS1 show a single strand of the activation loop folded across the active site parallel to the P-loop, potentially blocking the interaction with substrate peptides.²⁹ However, in these cases, the kinase adopts a DFG-in conformation on ligand binding and the α C-helix is preserved.

Within the unusual kinase ATP-site conformation, the ligand **2** bound at the hinge region, with the imidazo[1,2-*b*]pyridazine ring sandwiched between L714 in the activation loop and V586 in the β 2-strand, C-terminal to the P-loop (Figure 3B). Canonical hydrogen bonds were made from the imidazo[1,2-*b*]pyridazine N1 and 8-NH to the C645 NH (3.1 Å) and C=O (3.0 Å) functionalities, respectively. This closely resembled the binding modes described for 8-amino-imidazo[1,2-*b*]pyridazines in other kinases.^{28,29,37,38} An additional hydrogen bond (2.8 Å) was observed between the indazole NH and Y628, presumably contributing to stabilizing the tyrosine “down” conformation. The indazole occupied a hydrophobic pocket formed by the gatekeeper residue I642, F712 of the DFG motif, F725 from the activation loop, and the catalytic lysine K599. The 6-chloro substituent of **2** packed closely against the β -sheet surface formed by L577 and G578 of the P-loop and H723 and S724 of the activation loop. The cyclopropylmethyl side chain of **2** reached the edge of the ATP site and was oriented to provide a vector out into solvent.

The unusual binding mode seen for 2-IRE1 α was independently reproduced with a close analogue, **33** (PDB 6HV0), in which the cyclopropylmethyl group was replaced by an isopropyl chain (Figure S4), supporting the likely biological relevance of the structure. Furthermore, the observed binding mode was consistent with the structure–activity relationships described above for the indazole-substituted 8-amino-imidazo[1,2-*b*]pyridazines, specifically the requirement for a hydrogen bond donor corresponding to the indazole N(1)–H (Table 1) and the tolerance of a wide range of substitution of the 8-amino group on the imidazo[1,2-*b*]pyridazine core (Table 2). Modeling of the more potent compound **26** into the conformation of IRE1 α observed in the crystal structures reproduced this binding mode, with the suggestion of an additional hydrogen bond from the cyclohexylamine to E651 on the surface of the protein (Figure S5).

The unusual DFG-up inactive conformation of the kinase domain of 2- and 33-IRE1 α differed considerably from other active and inactive kinase conformations reported for ligand-bound structures of IRE1 α (Figure 3C,D).^{4,6,22,23} We

previously described the IRE1 α kinase inhibitor-RNase activator **1** that stabilized a classical DFG-in, active conformation of the kinase with the activation loop extended away from the active site, mimicking IRE1 α autophosphorylation and activating the RNase function through competent dimerization of the endonuclease domain.⁶ In contrast, a large sulfonamide inhibitor (named compound **16**), although it also bound to a DFG-in conformation of the kinase, was found to cause a shift of the α C-helix that was incompatible with the formation of the RNase domain dimer.²³ A type III inhibitor of IRE1 α , GSK2850163, has been described that occupied a pocket adjacent to the hinge region of the kinase and promoted a DFG-out kinase conformation, with the activation loop directed across the active site and the α C-helix further shifted and rotated away from the active conformation.²² In the latter two cases, although the active kinase conformation was disrupted, the α C-helix remained intact. For **2** and **33**, our data showed a striking disruption of the α C-helix, as well as a distinctive refolding of the activation loop around the bound inhibitor. This conformation is incompatible with the back-to-back dimerization required to form an active endoribonuclease domain dimer (Figure 3E). The dimerization interface in the kinase domain is formed by the loops $\beta(-1)$ – $\beta(0)$ and $\beta(2)$ – $\beta(3)$ from each monomer.⁶ Compared to the active IRE1 α dimer structure represented by 1-IRE1 α , the binding of **2** and **33** shifted the position of the kinase domain relative to the endonuclease domain such that dimerization at the kinase domain would lead to steric clashes of the endoribonuclease domains.

We were unable to obtain a crystal structure of a 2-aminobenzimidazole-substituted analogue bound to IRE1 α . Modeling of **9**, the closest analogue to **2**, into the structure of 2-IRE1 showed that alignment of the imidazo[1,2-*b*]pyridazine cores of the two inhibitors resulted in a clash between the 2-aminobenzimidazole substituent and residue Y628. When Y628 was allowed to move from the “down” orientation observed in 2-IRE1 to the “up” conformation observed in other IRE1 α structures, this minimal change resulted in a satisfactory binding mode for the prototypical 2-(*N*-phenyl)-aminobenzimidazole **9** (Figure 3F). The model retained binding of the imidazo[1,2-*b*]pyridazine at the hinge region and proposed a 180° rotation of the 2-aminobenzimidazole relative to the indazole substituent of **2** such that a new hydrogen bond was formed between the 2-amino group and D711 of the DFG motif. The terminal phenyl group occupied the space vacated by Y628 and packed against this residue now in its upward conformation. The introduction of a hydrogen bond to the DFG motif was consistent with precedent for other 2-aminobenzimidazole kinase inhibitors, where this functionality is often an isostere for urea-based inhibitors that bind to DFG-out conformations, as we had originally




Figure 4. Compounds **26** and **31** inhibit IRE1 α oligomerization, IRE1 α autophosphorylation, IRE1 α RNase activity, XBP1s protein expression, and XBP1-dependent transcription in human cells. (A) Inhibition of tunicamycin-induced IRE1 α oligomerization, measured by fluorescent foci formation in HEK293 cells stably transfected with doxycycline-inducible GFP-IRE1 α after 5 h treatment with inhibitors (0–10 μ M) in the absence or presence of tunicamycin (quantification of image fields from $n = 2$ experiments plotted separately). Dox = doxycycline, T = tunicamycin (10 μ g/mL). (B) Inhibition of tunicamycin-induced pS724 IRE1 α autophosphorylation as measured by capillary electrophoresis immunoassay (simple Western) relative to total IRE1 α . Data shown for a single experiment representative of $n = 3$. (C) Inhibition of tunicamycin-induced XBP1s protein expression in H929 cells as measured by immunofluorescent assay (quantification of image fields from $n > 3$ experiments). (D) Inhibition of tunicamycin-induced XBP1s-dependent transcription of DNAJB9 mRNA as measured by real-time quantitative polymerase chain reaction (RT-qPCR). Data shown for a single experiment representative of $n = 3$. Tm = tunicamycin.

speculated in developing the series. Moreover, the modeled hydrogen bond to D711 was consistent with the observed structure–activity relationships, where methylation of the 2-amino group or imidazole nitrogens reduced activity (Table 1). The combination of multiple kinase conformational disruptions accompanying binding of the indazole and amino-benzimidazole scaffolds can account for the high IRE1 α kinase selectivity of **26** and **31** (Figure 2). For **26**, a discrete set of kinases in the CAMK and TK subfamilies were also inhibited. For this ligand, we cannot exclude the possibility that an alternative binding mode where the indazole contributes the donor–acceptor hinge-binding motif may be accessible in

some kinases.^{39,40} Interestingly, while the majority of residues forming the binding site of **2** and **33** to IRE1 α are identical in the sequence of the isoform IRE1 β , the histidine H723 in IRE1 α is replaced by a cysteine residue (C671) in IRE1 β (Figure S3B).³⁴ Since hydrogen bonding of the imidazole side chain of H723 to E651 appeared important for the unusual activation loop fold in the structures **2** and **33** bound to IRE1 α , we speculate that the absence of this residue may in part be involved in the observed selectivity of the compounds for IRE1 α over IRE1 β . The other major local difference (A646 in the hinge corresponds to R594 in IRE1 β)³⁴ involves a side chain directed away from the binding site.

To confirm the functional consequences of the unusual binding modes of the inhibitors, we investigated the effects of **26** and **31** on ER stress-induced IRE1 α signaling outputs in human cells. The effects of the compounds on IRE1 α oligomerization were determined in HEK293 cells expressing doxycycline-inducible green fluorescent protein (GFP)-labeled IRE1 α that forms quantifiable fluorescent foci in the ER membrane under stress conditions⁴¹ (Figure 4A). GFP-IRE1 α foci produced upon treatment with tunicamycin were dose-dependently reduced by **26** (IC₅₀ = 1.88 ± 0.09 μ M) and **31** (IC₅₀ = 0.74 ± 0.03 μ M), indicating inhibition of IRE1 α oligomer formation. No stimulation of GFP-IRE1 α foci formation was observed for either compound on its own. Thus, the compounds are full inhibitors of oligomerization in cells and do not show partial activation of IRE1 α through occupation of the nucleotide-binding site.

Compounds **26** and **31** inhibited both tunicamycin- and thapsigargin-induced IRE1 α -dependent splicing of XBP1 luciferase fusion mRNA in HEK293 cells (Table 3 and Figure S6) with equivalent potencies (IC₅₀ 0.68–1.63 μ M). In parallel, inhibition of tunicamycin-induced production of endogenous XBP1s mRNA was demonstrated in H929 myeloma cells using RT-qPCR at similar concentrations (Figure S7). The expression of the spliced transcription factor XBP1s following ER stress was measured by immunofluorescent staining in H929 myeloma cells (Figure 4C). Tunicamycin-induced expression of XBP1s protein was inhibited by **26** and **31** with similar potencies to the inhibition of IRE1 α oligomerization and RNase activities in cells. The expected downstream effect on XBP1s-dependent transcription in H929 cells was confirmed by monitoring production of the mRNA coding for DNAJB9, an ER-resident molecular chaperone regulated by XBP1s⁸ (Figure 4D). Inhibition of IRE1 α autophosphorylation in H929 cells was also observed on treatment with **26** and **31** (Figures 4B and S8), although full blockade appeared to require higher concentrations than the oligomerization and RNase functions. This is consistent with the proposed model for IRE1 α activation, where conformationally productive oligomerization is the critical step in activating the endoribonuclease,⁴ while autophosphorylation contributes to stabilizing the active oligomers⁶ and XBP1-independent signaling to JNK through the binding of TRAF2.¹⁰ Previous studies by our group⁶ and others⁴ indicate that the trans-autophosphorylation of IRE1 α proceeds through a face-to-face encounter of IRE1 α protomers distinct from the back-to-back arrangement essential for activation of the RNase function.

DISCUSSION AND CONCLUSIONS

Through screening analogues of a type I IRE1 α kinase inhibitor that activates the RNase function through binding to a classical DFG-in kinase conformation, we unexpectedly discovered a closely related series of imidazo[1,2-*b*]pyridazin-8-amine kinase inhibitors that also inhibited the RNase. This surprising finding challenged our initial assumption that type II or type III kinase inhibitors binding to a DFG-out conformation of the kinase would be needed to prevent IRE1 α dimerization and activation of the RNase.

We increased the potency of the imidazo[1,2-*b*]pyridazin-8-amine using design hypotheses that assumed a type I binding mode of the core scaffold, leading to a series of indazoles, while further substitution generated 2-phenyl-benzimidazoles designed as potential type II inhibitors. However, crystal

structures of the indazoles **2** and **33** bound to IRE1 α showed the protein to adopt a highly unusual conformation, with the DFG motif in an intermediate “up” position and substantial disordering of the α C-helix. These structures and models derived from them accounted for the structure–activity relationships of the inhibitors, showing how a type I scaffold could promote a previously unreported conformation of the kinase domain that is incompatible with RNase domain back-to-back dimerization required for activation of the RNase function. The binding mode emphasized the role of the hydrophobic spine residue Y628 of IRE1 α in compound binding and kinase conformational control.^{6,42}

Other kinase signaling pathways have been observed to be modulated through transactivation of dimers controlled allosterically by kinase site occupation.⁴³ Notably, ligand-promoted heterodimerization of inhibitor-bound BRAF with CRAF results in paradoxical activation of RAF signaling by some BRAF inhibitors.^{44,45} Kinase site inhibitors that can simultaneously suppress the catalytic function of kinase monomers and their dimerization with uninhibited partners are therefore a potentially useful therapeutic modality.⁴⁶ Certain pseudokinases that lack intrinsic enzyme function also exploit dimerization to regulate signaling pathways and may be amenable to pharmacological intervention through nucleotide-binding-site ligands that prevent dimerization.⁴⁷

The most advanced compound we studied showed nanomolar potency for biochemical inhibition of the kinase and RNase and, importantly, was highly selective for IRE1 α over other kinases. It is possible that the high selectivity of **31** reflects binding to the unusual IRE1 α kinase conformation incorporating multiple disruptions, as modeled for the analogue **9**. Although elements of the conformational disruption of the IRE1 α kinase domain have been seen separately in other contexts,^{22,23,28,29,35,36} to our knowledge, they have not been observed occurring simultaneously. Our findings thus increase the repertoire of conformations discovered for IRE1 α and provide a means to achieve high specificity for IRE1 α inhibition over other kinases, with reliable translation of kinase ATP-site occupation into RNase inhibition.

We confirmed that compounds engaging the newly discovered IRE1 α conformation resulted in the inhibition of ER stress-induced signaling through IRE1 α in multiple human cell types, resulting in inhibition of XBP1-dependent transcription. We determined substantial inhibition of the IRE1 α signaling pathways to occur in cells at concentrations of **26** and **31** between ca. 1 and 2 μ M in short-term assays. Selective IRE1 α kinase-endoribonuclease inhibitors may have utility in situations where direct cytotoxicity is not the desired outcome of IRE1 α -XBP1s inhibition, such as the modulation of XBP1s-dependent suppression of dendritic immune cell function. The identification of compounds **26** and **31** and their binding mode demonstrates a new means to achieve highly selective inhibition of IRE1 α , which may be important in such contexts where the biology of untransformed host cells is targeted.⁴⁸

EXPERIMENTAL SECTION

IRE1 α Autophosphorylation Assay. Inhibition of IRE1 α autophosphorylation was measured using a dissociation-enhanced lanthanide fluorescence immunoassay (DELFI) as described previously.³¹ Briefly, dephosphorylated IRE1 α G547-L977 (700 nM) was incubated for 25 min with 100 μ M ATP in 15 μ L of assay buffer (40 mM Tris (pH 7.5), 20 mM MgCl₂, and 1 mM 1,4-

dithiothreitol (DTT)). The assay was stopped by the addition of 40 mM ethylenediaminetetraacetic acid. Samples were transferred to a 384-well high-binding plate and incubated overnight at 4 °C. The plates were washed three times in 0.1% Tween-20, followed by blocking in 5% nonfat skimmed milk in phosphate-buffered saline (PBS) for 30 min at 37 °C. The plates were washed again before application of α -pS724 phospho-specific IRE1 α primary antibody³¹ (160 pg/mL) in PBS to each well and incubated for 1.5 h at 37 °C. The plates were washed before addition of a europium-labeled α -rabbit secondary antibody (PerkinElmer Life Sciences). Another wash step was followed by the addition of DELFIA enhancement solution (PerkinElmer Life Sciences). Assay plates were read on an EnVision multimode plate reader (PerkinElmer Life Sciences).

IRE1 α RNase Assay. Inhibition of IRE1 α endoribonuclease activity was measured using a FRET de-repression assay monitoring cleavage of a 29-nucleotide stem-loop RNA containing the XBP1 cleavage site sequence and labeled with a fluorescence emitter (fluorescein amidite (FAM)) and a fluorescence quencher (Black Hole Quencher (BHQ)) at the 5' and 3' ends, respectively (Figure S2), as described previously.^{30,31} Briefly, varying volumes of compound in DMSO or DMSO alone were added to a low-volume 384-well plate (3676, Corning) to give final concentrations ranging from 100 μ M to 0.313 nM using an Echo acoustic liquid dispenser (Labcyte, CA). Nonphosphorylated IRE1 α G547-L977 was added to a final concentration of 200 nM. After incubating for 30 min at 30 °C, hairpin RNA XBP1 substrate mimic labeled with fluorescein and Black Hole Quencher (5' FAM-GAACAAGAUUCCGCA-GCAUAUACAGUUC-3' BHQ, Eurofins MWG Operon, Germany) was added to 100 nM final concentration. After incubation for a further 15 min at 30 °C, the fluorescein fluorescence was measured on an EnVision multimode plate reader (PerkinElmer Life Sciences). Fluorescence in the presence of compound was expressed relative to that of DMSO alone (no compound).

IRE1 α ATP-Site Binding Assay. Compound binding to IRE1 α was measured using a LanthaScreen Eu Kinase binding FRET assay monitoring the displacement of an ATP-site tracer by inhibitors. Briefly, a master mix of (7.5 μ L) 50 nM dephosphorylated IRE1 α G547-L977, 2 nM biotinylated anti-his-tag antibody (PV6089, Thermo Fisher Scientific), 2 nM streptavidin–europium (PV5899, Thermo Fisher Scientific) diluted in assay buffer (PV3189, Thermo Fisher Scientific), and 1 mM 1,4-dithiothreitol (DTT) (D0632, Sigma-Aldrich) was incubated with 7.5 μ L of 75 nM tracer (Tracer 236, Thermo Fisher Scientific) in assay buffer for 60 min at rt. During the incubation, the 384-well white low-volume plate (3674, Corning) was covered with foil. Assay plates were read on an EnVision multimode plate reader (PerkinElmer Life Sciences).

X-ray Crystallography of 2-IRE1 α (PDB 6HX1). Determination of the structure of 2-IRE1 α was conducted by Proteros Biostructures GmbH (Martinsried, Germany). Expression, purification, and crystallization of IRE1 α with compound were performed by analogy to previously reported protocols.⁶ Crystals were flash-frozen and data were collected at 100 K at the Swiss Light Source (PXI/X06SA, PILATUS 6 M detector; SLS, Villigen, Switzerland) using cryogenic conditions. Data were processed using the programs XDS and XSCALE.⁴⁹ The structure of apo-IRE1 α was solved by molecular replacement using a previously solved structure of IRE1 α as a search model. Subsequent model building and refinement was performed according to standard protocols with the software packages CCP4⁵⁰ and COOT.⁵¹ For the calculation of the free *R*-factor, 5.4% of measured reflections were excluded from the refinement procedure (see Table S2). The ligand parameterization and generation of the corresponding library files were carried out with CORINA (Molecular Networks, GmbH). The water model was built with the “Find waters” algorithm of COOT by placing water molecules in peaks of the Fo–Fc map contoured at 3.0, followed by refinement with REFMAC5⁵² and checking all waters with the validation tool of COOT. The criteria for the list of suspicious waters were: *B*-factor greater than 80 Å², 2Fo–Fc map less than 1.2 σ , and distance to the closest contact less than 2.3 Å or more than 3.5 Å. The suspicious water molecules and those in the ligand binding site (distance to ligand less than 10 Å)

were checked manually. The occupancy of side chains in negative peaks in the Fo–Fc map (contoured at -3.0σ) was set to zero and subsequently to 0.5 if a positive peak occurred after the next refinement cycle.

In Silico Chemistry. The enzyme–inhibitor crystal structure of 2-IRE1 α (PDB 6HX1) was prepared for modeling using Protein Preparation Wizard in Maestro,⁵³ and all water molecules, apart from that interacting with residues L577 and H723, were removed. To propose predicted binding modes of the inhibitors, Glide (grid-based ligand docking with energetics)⁵⁴ was used for the docking experiments. The receptor grid (model A; for 26 bound to IRE1 α) was defined by a grid box of 25 \times 25 \times 25 Å³ with a default inner box (10 \times 10 \times 10 Å³) centered on the ligand 2 in 6HX1. For the “Y628-up” conformation (model B; for 9 bound to IRE1 α), the side-chain orientation of residue Tyr628 in 6HX1 was flipped from the observed rotamer to the most probable rotamer without steric clashes according to the Schrödinger in-built rotamer library, energy-minimized, and a Glide receptor grid subsequently prepared as described above.

Ligands were prepared using LigPrep⁵⁵ applying the OPLS_2005 force field with possible tautomeric and ionization states in the pH range 5.0–9.0 generated. Using Glide Extra Precision (XP) settings, flexible docking of ligands was conducted with the minimal constraints defined as satisfying at least one H-bonding interaction with either residue R643 or C645 (kinase hinge region interactions), analogous to the interactions observed in the structure of 2-IRE1 α . Model A was used for the binding mode predictions of 26, whereas model B was applied to predict the binding mode of 9.

Hit compound 2 was analyzed for potential pan-assay interference behaviors using open access in silico tools (<http://zinc15.docking.org/patterns/home>), and no substructural alerts were returned. Specific inhibition of IRE1 α kinase was demonstrated in two independent assay formats for 2 and active analogues (Tables 1 and 2).

General Synthetic Chemistry. Reactions were carried out under N₂. Organic solutions were dried over MgSO₄ or Na₂SO₄. Starting materials and solvents were purchased from commercial suppliers and were used without further purification. Reactions heated by microwave irradiation were carried out using a Biotage Initiator microwave reactor. Reactions in sealed tubes were carried out in pressure vessels with shield protection. Ion-exchange chromatography was performed using ISOLUTE Flash SCX-II (acidic) or Flash NH2 (basic) resin cartridges. Silica column chromatography was performed using Biotage SP1 or Isolera medium-pressure chromatography systems, using prepacked silica gel cartridges (normal phase, Biotage SNAP KP-Si; reverse phase, Biotage SNAP Ultra C18). Preparative high-performance liquid chromatography (HPLC) was carried out at rt using a 1200 Series Preparative HPLC (Agilent, Santa Clara) over a 15 min gradient elution from 60:40 to 0:100 water/MeOH (both modified with 0.1% formic acid) at flow rates of 5, 20, or 40 mL/min depending on the column size used. Standard injections of 500 μ L to 2 mL (with needle wash) of the sample were made onto ACE 5 C18-PPF columns (5 μ m, 250 \times 10/250 \times 21.2/250 \times 30 mm², Advanced Chromatography Technologies, Aberdeen, U.K.). UV–vis spectra were acquired at 254 nm on a 1200 Series Prep Scale diode array detector (Agilent, Santa Clara). NMR spectra were recorded on Bruker AMX500 or AV600 instruments using internal deuterium locks. Chemical shifts (δ) are reported relative to tetramethylsilane (δ = 0) and/or referenced to the solvent in which they were measured. Compounds were assessed for purity by tandem HPLC–MS. Combined HPLC–MS analyses were recorded using an Agilent 6210 time-of-flight (ToF) HPLC–MS with a Merck Purospher STAR column (RP-18e, 30 \times 4 mm²) or a Waters Xevo G2QToF HPLC–MS with a Phenomenex Kinetex C18 column (30 \times 2.1 mm², 2.6 μ m, 100 Å). Analytical separation was carried out at 40 °C with UV detection at 254 nm, and ionization was by positive-ion electrospray. The mobile phase was a mixture of MeOH (solvent A) and water (solvent B), both containing formic acid at 0.1%. Gradient elution from 10:90 (A/B) to 90:10 (A/B) was carried out over 2 min (flow rate: Agilent, 3 mL/min; Xevo, 0.5 mL/min) or 4 min (flow rate: Agilent, 1.5 mL/min; Xevo, 0.3 mL/min). Biologically evaluated

compounds gave >95% purity as determined by these methods (Table S2).

6-Chloro-N-(cyclopropylmethyl)-3-(1H-indazol-5-yl)imidazo[1,2-b]pyridazin-8-amine (2). 4-Bromo-6-chloropyridazin-3-amine (10.0 g, 48.1 mmol) and 2-chloroacetaldehyde (31.8 mL, 250 mmol; 50% w/w aqueous solution) in EtOH (67 mL) were stirred at 50 °C for 22 h. The mixture was cooled to rt, concentrated, and partitioned between CH₂Cl₂ (300 mL) and saturated aqueous NaHCO₃ (200 mL). The aqueous phase was extracted with CH₂Cl₂ (150 mL). The combined organic layers were dried, filtered, and evaporated to dryness to give 8-bromo-6-chloroimidazo[1,2-b]pyridazine (11.2 g, quantitative) that was taken to the next step without further purification. ¹H NMR (500 MHz, CDCl₃) δ 8.01 (d, *J* = 1.2 Hz, 1H), 7.84 (d, *J* = 1.1 Hz, 1H), 7.40 (s, 1H); ¹³C NMR (126 MHz, CDCl₃) δ 145.9, 137.0, 134.8, 124.2, 121.2, 118.8; liquid chromatography mass spectrometry (LCMS) (2 min) electrospray ionization (ESI), (*m/z*)_R = 1.04 min, *m/z* (ESI⁺) 233 (M + H⁺). *N*-Bromosuccinimide (5.17 g, 29.0 mmol) was added to a solution of 8-bromo-6-chloroimidazo[1,2-b]pyridazine (4.50 g, 19.4 mmol) in CHCl₃ (59 mL) at 0 °C. The mixture was warmed to rt and stirred for 18 h. The mixture was partitioned between saturated aqueous NaHCO₃ (150 mL) and CH₂Cl₂ (100 mL × 2). The combined organic layers were dried, filtered, and evaporated to dryness. Silica column chromatography, eluting with 30% EtOAc–hexanes, gave 3,8-dibromo-6-chloroimidazo[1,2-b]pyridazine (3) (5.05 g, 84%). ¹H NMR (500 MHz, CDCl₃) δ 7.85 (s, 1H), 7.46 (s, 1H); ¹³C NMR (126 MHz, CDCl₃) δ 147.0, 137.5, 135.3, 124.3, 121.4, 103.2; LCMS (2.0 min) *t*_R = 1.36 min, *m/z* (ESI⁺) 311 (M + H⁺). Cyclopropanemethylamine (4.82 mL, 56.2 mmol) was added to a stirred solution of 3 (3.50 g, 11.24 mmol) in THF (56 mL) at rt. After 3 h, the mixture was evaporated and partitioned between saturated aqueous NaHCO₃ (200 mL) and CH₂Cl₂ (100 mL × 2). The combined organic layers were washed with brine (100 mL), dried, and evaporated to dryness. Silica column chromatography, eluting with 15–20% EtOAc–hexanes, gave 3-bromo-6-chloro-N-(cyclopropylmethyl)imidazo[1,2-b]pyridazin-8-amine (4) (3.20 g, 93%). ¹H NMR (500 MHz, CDCl₃) δ 7.49 (s, 1H), 6.04 (s, 1H), 6.00 (br t, *J* = 5.3 Hz, 1H), 3.17 (dd, *J* = 5.2, 7.1 Hz, 2H), 1.20–1.17 (m, 1H), 0.69–0.66 (m, 2H), 0.36–0.33 (m, 2H); ¹³C NMR (126 MHz, CDCl₃) δ 149.5, 142.9, 133.1, 130.9, 101.1, 92.2, 47.8, 10.0, 3.8 (2C); LCMS (2.0 min) *t*_R = 1.63 min, *m/z* (ESI⁺) 303 (M + H⁺). N₂ was bubbled for 10 min through a mixture of 4 (0.096 g, 0.318 mmol), 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole (0.121 g, 0.350 mmol), and aq Na₂CO₃ (2 M; 0.637 mL, 1.27 mmol) in 1,4-dioxane (1.59 mL). Pd(OAc)₂ (7.1 mg, 0.032 mmol) and 1,1'-bis(di-*tert*-butylphosphino)ferrocene (0.017 g, 0.032 mmol) were added and the mixture was heated at 135 °C in a sealed tube for 22 h. The mixture was cooled and purified by ion-exchange chromatography on acidic resin (5 g), eluting with 2 M NH₃ in MeOH. The fractions containing product were concentrated and purified by silica column chromatography, eluting with 5% MeOH–CH₂Cl₂, to give 2 (0.047 g, 44%). ¹H NMR (500 MHz, DMSO-*d*₆) δ 13.18 (s, 1H), 8.51 (t, *J* = 1.1 Hz, 1H), 8.19 (t, *J* = 1.2 Hz, 1H), 8.07–7.79 (m, 3H), 7.66 (dt, *J* = 8.9, 0.9 Hz, 1H), 6.34 (s, 1H), 3.32 (s, 2H), 1.23–1.14 (m, 1H), 0.51–0.45 (m, 2H), 0.35–0.27 (m, 2H); ¹³C NMR (126 MHz, DMSO-*d*₆) δ 147.6, 143.7, 139.1, 134.2, 132.9, 129.0, 128.8, 125.5, 122.9, 120.8, 118.4, 110.4, 90.6, 46.1, 10.2, 3.4 (2C); LCMS (2 min) *t*_R = 1.50 min, *m/z* (ESI⁺) 339 (M + H⁺); high-resolution mass spectrometry (HRMS) *m/z* calcd for C₁₇H₁₆N₆³⁵Cl (M + H) 339.1125, found 338.1133.

6-Chloro-N-(cyclopropylmethyl)-3-(1-methyl-1H-indazol-5-yl)imidazo[1,2-b]pyridazin-8-amine (5). A mixture of 1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole (0.086 g, 0.333 mmol), 4 (0.084 g, 0.278 mmol), aqueous Na₂CO₃ (2 M; 0.56 mL, 1.11 mmol), and Pd(OAc)₂ (6.23 mg, 0.028 mmol), and 1,1'-bis(di-*tert*-butylphosphino)ferrocene (0.013 g, 0.028 mmol) in 1,4-dioxane (1.4 mL) was heated at 120 °C in a sealed tube for 22 h. The mixture was cooled, absorbed onto silica gel, and purified by silica column chromatography, eluting with 70% EtOAc–hexanes, to give 5 (0.046 g, 47%). ¹H NMR (500 MHz, DMSO-*d*₆) δ 8.52 (dd, *J*

= 1.6, 0.8 Hz, 1H), 8.17 (d, *J* = 1.0 Hz, 1H), 8.02–7.93 (m, 3H), 7.76 (dt, *J* = 9.0, 0.9 Hz, 1H), 6.34 (s, 1H), 4.09 (s, 3H), 3.31–3.17 (m, 2H), 1.21–1.15 (m, 1H), 0.51–0.44 (m, 2H), 0.35–0.26 (m, 2H); ¹³C NMR (126 MHz, DMSO-*d*₆) δ 148.1, 144.1, 139.3, 133.5, 133.4, 129.5, 129.1, 125.9, 124.0, 121.4, 118.9, 110.5, 91.1, 46.5, 35.9, 10.7, 3.9 (2C); LCMS (2 min) *t*_R = 1.56 min, *m/z* (ESI⁺) 353 (M + H⁺); HRMS *m/z* calcd for C₁₈H₁₈N₆³⁵Cl (M + H) 353.1281, found 353.1275.

6-Chloro-N-(cyclopropylmethyl)-3-(1H-indazol-6-yl)imidazo[1,2-b]pyridazin-8-amine (6). N₂ was bubbled for 10 min through a mixture of 4 (0.073 g, 0.242 mmol), 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole (0.065 g, 0.266 mmol), and aqueous Na₂CO₃ (2 M; 0.48 mL, 0.968 mmol) in 1,4-dioxane (1.21 mL). Pd(OAc)₂ (5.4 mg, 0.024 mmol) and 1,1'-bis(di-*tert*-butylphosphino)ferrocene (0.013 g, 0.024 mmol) were added and the mixture was heated at 135 °C in a sealed tube for 15 h. The mixture was cooled and purified by ion-exchange chromatography on acidic resin (5 g), eluting with 2 M NH₃ in MeOH. The fractions containing product were concentrated and purified by silica column chromatography, eluting with 5% MeOH–CH₂Cl₂, to give 6 (0.042 g, 51%). ¹H NMR (500 MHz, DMSO-*d*₆) δ 13.32–13.16 (m, 1H), 8.49 (q, *J* = 1.1 Hz, 1H), 8.12–8.08 (m, 2H), 8.03 (t, *J* = 6.1 Hz, 1H), 7.86 (dd, *J* = 8.5, 0.9 Hz, 1H), 7.71 (dt, *J* = 8.5, 1.0 Hz, 1H), 6.40 (d, *J* = 1.5 Hz, 1H), 3.34 (s, 2H), 1.24–1.14 (m, 1H), 0.53–0.45 (m, 2H), 0.35–0.28 (m, 2H); ¹³C NMR (126 MHz, DMSO-*d*₆) δ 147.7, 143.7, 140.0, 139.9, 133.5, 130.0, 128.3, 126.0, 121.9, 120.8, 119.5, 107.0, 90.9, 46.1, 10.2, 3.4 (2C); LCMS (4 min) *t*_R = 3.21 min, *m/z* (ESI⁺) 339 (M + H⁺); HRMS *m/z* calcd for C₁₇H₁₅N₆³⁵Cl (M + H) 339.1119, found 339.1115.

6-Chloro-N-(cyclopropylmethyl)-3-(1H-indol-5-yl)imidazo[1,2-b]pyridazin-8-amine (7). Prepared from 4 and (1H-indol-5-yl)-boronic acid using the method described for 6 to give 7 (50%). ¹H NMR (500 MHz, DMSO-*d*₆) δ 11.23 (s, 1H), 8.29–8.20 (m, 1H), 7.88 (t, *J* = 6.1 Hz, 1H), 7.84 (s, 1H), 7.68 (dd, *J* = 1.7, 8.5 Hz, 1H), 7.50 (dt, *J* = 0.9, 8.6 Hz, 1H), 7.40 (t, *J* = 2.8 Hz, 1H), 6.53 (ddd, *J* = 0.9, 1.9, 3.1 Hz, 1H), 6.30 (s, 1H), 3.25 (s, 2H), 1.19 (dd, *J* = 2.0, 4.9 Hz, 1H), 0.52–0.45 (m, 2H), 0.34–0.28 (m, 2H); ¹³C NMR (126 MHz, DMSO-*d*₆) δ 147.4, 143.6, 135.4, 132.5, 129.9, 128.4, 127.6, 126.2, 120.5, 119.3, 118.6, 111.6, 101.6, 90.3, 46.1, 10.3, 3.4 (2C); LCMS (2 min) *t*_R = 1.52 min, *m/z* (ESI⁺) 338 (M + H⁺); HRMS *m/z* calcd for C₁₈H₁₆N₅³⁵Cl (M + H) 338.1172, found 338.1161.

6-Chloro-N-(cyclopropylmethyl)-3-(1H-benzo[d]imidazol-5-yl)imidazo[1,2-b]pyridazin-8-amine (8). Prepared from 4 and 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-benzo[d]imidazole using the method described for 6 with purification by preparative HPLC to give 8 (5%). ¹H NMR (500 MHz, DMSO-*d*₆) δ 12.60 (d, *J* = 36.4 Hz, 1H), 8.39 (d, *J* = 8.9 Hz, 1H), 8.28 (s, 1H), 7.95 (d, *J* = 15.4 Hz, 2H), 7.88–7.60 (m, 2H), 6.34 (s, 1H), 3.25 (s, 2H), 1.23–1.14 (m, 1H), 0.52–0.45 (m, 2H), 0.35–0.28 (m, 2H); ¹³C NMR (126 MHz, DMSO-*d*₆) δ 148.0, 144.1, 143.4, 133.4, 129.5 (2C), 122.7, 121.6, 91.0, 46.5, 10.7, 3.9 (2C); LCMS (2 min) *t*_R = 1.19 min, *m/z* (ESI⁺) 339 (M + H⁺); HRMS *m/z* calcd for C₁₇H₁₅N₆³⁵Cl (M + H) 339.1125, found 339.1127.

6-Chloro-N-(cyclopropylmethyl)-3-(2-(phenylamino)-1H-benzo[d]imidazol-5-yl)imidazo[1,2-b]pyridazin-8-amine (9). A mixture of 5-bromo-2-chloro-1H-benzo[d]imidazole (5.00 g, 21.6 mmol) and aniline (10.1 mL, 110 mmol) was heated by microwave irradiation at 180 °C for 60 min. The mixture was cooled, diluted with EtOAc (60 mL), and washed with water (60 mL) and brine (60 mL). The organic layer was dried and concentrated. Silica chromatography, eluting with 0–2% MeOH–CH₂Cl₂, gave 5-bromo-N-phenyl-1H-benzo[d]imidazol-2-amine (4.67 g, 75%). ¹H NMR (500 MHz, DMSO-*d*₆) δ 11.02 (s, 1H), 9.54 (s, 1H), 7.76–7.69 (m, 2H), 7.46 (s, 1H), 7.35–7.27 (m, 2H), 7.24 (d, *J* = 8.2 Hz, 1H), 7.11 (dd, *J* = 2.0, 8.4 Hz, 1H), 6.98–6.91 (m, 1H); ¹³C NMR (126 MHz, DMSO-*d*₆) δ 151.4, 140.5, 128.8 (2C), 122.9, 122.2, 120.9, 118.1, 117.9, 117.3 (2C), 112.1, 111.0; LCMS (2 min) *t*_R = 0.95 min, *m/z* (ESI⁺) 288 and 290 (M + H⁺); HRMS *m/z* calcd for C₁₃H₁₀N₃⁷⁹Br (M + H) 288.0136, found 288.0148. DMAP (0.4 g, 3.24 mmol) and di-*tert*-butyl-dicarbonate (8.84 g, 40.5 mmol) were added to a solution of 5-

bromo-*N*-phenyl-1*H*-benzo[*d*]imidazol-2-amine (4.67 g, 16.2 mmol) in dry THF (160 mL). The mixture was stirred at rt for 16 h and then concentrated. The residue was dissolved in EtOAc (100 mL) and washed with water (100 mL) and brine (100 mL). The organic layer was dried and concentrated. Silica chromatography, eluting with 0–2% MeOH-CH₂Cl₂, gave *tert*-butyl 5-bromo-2-((*tert*-butoxycarbonyl)(phenyl)amino)-1*H*-benzo[*d*]imidazole-1-carboxylate (7.9 g, quantitative) as a mixture of three di-Boc-protected isomers, which was used directly in the next step. LCMS (2 min) *t*_R = 1.69, 1.87, 1.91 min; *m/z* (ESI⁺) 488 and 490 (M + H⁺). A portion of the material (5.4 g, 11.1 mmol) was dissolved in dry 1,4-dioxane (110 mL) and stirred at rt. Bis(pinacolato)diboron (3.37 g, 13.3 mmol), 1,1'-bis(diphenylphosphino)ferrocene-palladium(II) dichloride (0.81 g, 1.11 mmol), and KOAc (2.17 g, 22.1 mmol) were added and the mixture was heated at 100 °C for 15 h. The mixture was cooled, filtered through celite, and concentrated. The residue was dissolved in EtOAc (50 mL) and washed with water (50 mL) and brine (50 mL). The organic layer was dried and concentrated. Silica chromatography, eluting with 0–10% EtOAc–cyclohexane, gave *tert*-butyl 2-((*tert*-butoxycarbonyl)(phenyl)amino)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1*H*-benzo[*d*]imidazole-1-carboxylate **13** (4.40 g, 74%) as a mixture of three di-Boc protected isomers, which was used directly in the next step. LCMS (2 min) *t*_R = 1.70 min, 1.78 min, 1.82 min; *m/z* (ESI⁺) 536 (M + H⁺). The mixture of isomers of **13** was reacted with **4** using the method described for **6** to give **9** (33%). ¹H NMR (500 MHz, DMSO-*d*₆) δ 11.14 and 11.01 (2 × s, 1H, NH); 9.53 and 9.50 (2 × s, 1H, NH), 8.06 (dd, *J* = 1.7, 11.6 Hz, 1H), 7.93–7.84 (m, 2H), 7.82–7.74 (m, 2H), 7.62 (td, *J* = 1.8, 7.9 Hz, 1H), 7.41 (dd, *J* = 8.2, 28.3 Hz, 1H), 7.33 (td, *J* = 2.9, 8.0 Hz, 2H), 6.94 (td, *J* = 1.2, 7.2 Hz, 1H), 6.31 (s, 1H), 3.25 (s, 2H), 1.23–1.15 (m, 1H), 0.53–0.45 (m, 2H), 0.35–0.29 (m, 2H); ¹³C NMR (126 MHz, DMSO-*d*₆) δ 151.4, 151.2, 147.5, 143.6, 143.2, 143.1, 140.7, 132.9, 132.7, 132.6, 129.7 (2C), 128.8, 128.5, 120.9, 120.7, 120.0, 119.9, 119.0, 117.2 (2C), 117.1, 115.8, 114.2, 109.5, 107.7, 90.3, 46.1, 10.2, 3.4 (2C); LCMS (2 min) *t*_R = 1.30 min, *m/z* (ESI⁺) 430 (M + H⁺); HRMS *m/z* calcd for C₂₃H₂₀N₇³⁵Cl (M + H) 430.1547, found 430.1537.

6-Chloro-*N*-(cyclopropylmethyl)-3-(2-(methyl(phenyl)amino)-1*H*-benzo[*d*]imidazol-5-yl)imidazo[1,2-*b*]pyridazin-8-amine (10). A mixture of 5-bromo-2-chloro-1*H*-benzo[*d*]imidazole (0.700 g, 3.02 mmol) and *N*-methylaniline (0.98 mL, 9.07 mmol) in EtOH (7 mL) was heated under microwave irradiation at 180 °C for 30 min. The mixture was cooled and concentrated. Silica chromatography, eluting with 10% EtOAc–cyclohexane and then with 50% EtOH–EtOAc, gave 5-bromo-*N*-methyl-*N*-phenyl-1*H*-benzo[*d*]imidazol-2-amine (0.800 g, 88%). ¹H NMR (500 MHz, DMSO-*d*₆) δ 12.85 (br s, 1H), 7.54 (d, *J* = 3.1 Hz, 4H), 7.45 (d, *J* = 1.6 Hz, 1H), 7.41 (tt, *J* = 2.7, 6.0 Hz, 1H), 7.30–7.23 (m, 2H), 3.56 (s, 3H); ¹³C NMR (126 MHz, DMSO-*d*₆) δ 152.1, 142.4, 130.1 (2C), 127.3, 125.4 (2C), 124.5, 114.5, 113.6, 113.3 (2 quaternary C not observed; NCH₃ obscured by solvent but detected in heteronuclear single quantum coherence NMR); LCMS (2 min) *t*_R = 0.94 min, *m/z* (ESI⁺) 302 and 304 (M + H⁺); HRMS *m/z* calcd for C₁₄H₁₂N₃⁷⁹Br (M + H) 302.0293, found 302.0300. A mixture of 5-bromo-*N*-methyl-*N*-phenyl-1*H*-benzo[*d*]imidazol-2-amine (0.800 g, 2.65 mmol), bis(pinacolato)diboron (0.690 g, 2.73 mmol), 1,1'-bis(diphenylphosphino)ferrocene-palladium(II) dichloride (0.190 g, 0.260 mmol), and KOAc (0.520 g, 5.30 mmol) in dry 1,4-dioxane (32 mL) was heated at 100 °C for 15 h. The mixture was cooled, filtered through celite, and concentrated. Ion-exchange chromatography on acidic resin, eluting with 2 M NH₃ in MeOH, gave *N*-methyl-*N*-phenyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1*H*-benzo[*d*]imidazol-2-amine (**14**) (0.29 g, 31%), which was used in the next step without further purification. LCMS (2 min) *t*_R = 1.03 min, *m/z* (ESI⁺) 350 (M + H⁺). The crude product **14** was reacted with **4** using the method described for **6** to give **10** (24%). ¹H NMR (500 MHz, DMSO-*d*₆) δ 11.45 (s, 1H), 8.01 (d, *J* = 1.6 Hz, 1H), 7.90 (t, *J* = 6.1 Hz, 1H), 7.84 (s, 1H), 7.57 (dd, *J* = 1.7, 8.2 Hz, 1H), 7.49–7.42 (m, 4H), 7.32 (d, *J* = 8.1 Hz, 1H), 7.27–7.20 (m, 1H), 6.30 (s, 1H), 3.34 (s, 3H), 3.24 (s, 2H), 1.24–1.11 (m, 1H), 0.52–0.43 (m, 2H),

0.35–0.26 (m, 2H); ¹³C NMR (126 MHz, DMSO-*d*₆) δ 154.8, 147.4, 144.7, 143.6, 132.6, 129.6, 129.4 (2C), 128.4, 124.8, 123.9 (2C), 119.5, 90.3, 46.1, 38.8, 10.2, 3.4 (2C), 5 quaternary C not observed; LCMS (2 min) *t*_R = 1.25 min, *m/z* (ESI⁺) 444 (M + H⁺); HRMS *m/z* calcd for C₂₄H₂₃N₇³⁵Cl (M + H) 444.1703, found 444.1703.

6-Chloro-*N*-(cyclopropylmethyl)-3-(1-methyl-2-(phenylamino)-1*H*-benzo[*d*]imidazol-5-yl)imidazo[1,2-*b*]pyridazin-8-amine (11). Isothiocyanatobenzene (0.20 mL, 0.23 mmol) and EDC (0.56 g, 2.9 mmol) were added to a stirred solution of *N*¹-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzene-1,2-diamine (**15**)⁵⁶ in dry THF (16 mL) at rt. The mixture was heated to 50 °C for 16 h. The mixture was concentrated and the residue was partitioned between water (30 mL) and EtOAc (30 mL). The organic layer was washed with brine (30 mL), dried, and concentrated. Ion-exchange chromatography on acidic resin, eluting with 2 M NH₃–MeOH, gave 1-methyl-*N*-phenyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1*H*-benzo[*d*]imidazol-2-amine (**16**) (0.25 g, 45%). ¹H NMR (500 MHz, DMSO-*d*₆) δ 8.94 (s, 1H), 7.82–7.90 (m, 2H), 7.65 (d, *J* = 0.9 Hz, 1H), 7.41 (dd, *J* = 1.1, 7.9 Hz, 1H), 7.29–7.35 (m, 3H), 6.96 (tt, *J* = 1.2, 7.4 Hz, 1H), 3.72 (s, 3H), 1.30 (s, 12H); ¹³C NMR (126 MHz, DMSO-*d*₆) δ 150.8, 141.4, 140.8, 136.8, 128.6 (2C), 126.3, 122.3, 121.1, 120.1, 117.9 (2C), 107.7, 83.2 (2C), 29.1, 24.7 (4C); LCMS (2 min) *t*_R = 1.10 min, *m/z* (ESI⁺) 350 (M + H⁺); HRMS *m/z* calcd for C₂₀H₂₅BN₃O₂ (M + H) 350.2043, found 350.2035. The product **16** was combined with **4** using the method described for **6** with purification by preparative HPLC to give **11** (15%). ¹H NMR (500 MHz, DMSO-*d*₆) δ 8.99 (s, 1H), 8.12 (dd, *J* = 0.5, 1.6 Hz, 1H), 7.94–7.87 (m, 4H), 7.71 (dd, *J* = 1.6, 8.3 Hz, 1H), 7.42 (d, *J* = 8.2 Hz, 1H), 7.38–7.30 (m, 2H), 6.97 (tt, *J* = 1.1, 7.3 Hz, 1H), 6.32 (s, 1H), 3.76 (s, 3H), 3.25 (s, 1H), 1.29–1.13 (m, 2H), 0.52–0.43 (m, 2H), 0.35–0.28 (m, 2H); ¹³C NMR (126 MHz, DMSO-*d*₆) δ 151.1, 147.5, 143.7, 141.8, 140.8, 134.0, 132.7, 129.5, 128.7, 128.6 (2C), 121.3, 121.2, 118.9, 118.0 (2C), 114.3, 108.2, 90.4, 46.1, 29.2, 10.2, 3.4 (2C); LCMS (2 min) *t*_R = 1.41 min, (ESI⁺) 444 (M + H⁺); HRMS *m/z* calcd for C₂₄H₂₃N₇³⁵Cl (M + H) 444.1703, found 444.1706.

6-Chloro-*N*-(cyclopropylmethyl)-3-(1-methyl-2-(phenylamino)-1*H*-benzo[*d*]imidazol-6-yl)imidazo[1,2-*b*]pyridazin-8-amine (12). Isothiocyanatobenzene was combined with *N*¹-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzene-1,2-diamine (**17**)⁵³ using the method described for **16** to give 1-methyl-*N*-phenyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1*H*-benzo[*d*]imidazol-2-amine (**18**) (17%). ¹H NMR (500 MHz, DMSO-*d*₆) δ 9.00 (s, 1H), 7.81–7.93 (m, 2H), 7.56 (d, *J* = 1.0 Hz, 1H), 7.42 (dd, *J* = 1.1, 7.8 Hz, 1H), 7.28–7.38 (m, 3H), 6.97 (tt, *J* = 1.1, 7.3 Hz, 1H), 3.73 (s, 3H), 1.31 (s, 12H); LCMS (2 min) *t*_R = 1.25 min, 350 (M + H⁺). The product **18** was combined with **4** using the method described for **6** to give **12** (38%). ¹H NMR (500 MHz, DMSO-*d*₆) δ 9.02 (s, 1H), 7.97 (d, *J* = 1.6 Hz, 1H), 7.96–7.91 (m, 2H), 7.91–7.87 (m, 2H), 7.81 (dd, *J* = 1.7, 8.3 Hz, 1H), 7.50–7.46 (m, 1H), 7.38–7.30 (m, 2H), 6.97 (tt, *J* = 1.1, 7.2 Hz, 1H), 6.32 (s, 1H), 3.77 (s, 3H), 3.25 (s, 2H), 1.26–1.13 (m, 1H), 0.52–0.45 (m, 2H), 0.35–0.28 (m, 2H); ¹³C NMR (126 MHz, DMSO-*d*₆) δ 151.3, 147.5, 143.6, 141.5, 140.7, 134.4, 132.7, 129.5, 128.7, 128.6 (2C), 121.3, 120.2, 120.0, 118.1 (2C), 115.9, 106.3, 90.4, 46.1, 29.1, 10.2, 3.5 (2C); LCMS (2 min) *t*_R = 1.41 min, *m/z* (ESI⁺) 444 (M + H⁺); HRMS *m/z* calcd for C₂₄H₂₃N₇³⁵Cl (M + H) 444.1703, found 444.1704.

6-Chloro-3-(1*H*-indazol-5-yl)-*N*-(tetrahydro-2*H*-pyran-4-yl)imidazo[1,2-*b*]pyridazin-8-amine (19). A mixture of **3** (150 mg, 0.482 mmol) and tetrahydro-2*H*-pyran-4-amine (73 mg, 1.5 equiv, 0.723 mmol) in THF (1.2 mL) was stirred at rt for 20 h. The mixture was diluted with THF (3 mL), and polystyrene–benzaldehyde resin (0.50 g, 0.723 mmol) was added. The suspension was gently stirred for 18 h at rt and then purified by ion-exchange chromatography on acidic resin (5 g), eluting with MeOH, 20% MeOH–CH₂Cl₂, and then 1:1 CH₂Cl₂/7 M NH₃ in MeOH. The basic fractions were concentrated and dried in vacuo to give 3-bromo-6-chloro-*N*-(tetrahydro-2*H*-pyran-4-yl)imidazo[1,2-*b*]pyridazin-8-amine (144 mg, 90%), which was used directly in the next step. A sample of the crude material (60 mg, 0.18 mmol) was added to a mixture of 5-

(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1*H*-indazole (53 mg, 0.216 mmol), 1,1'-bis(di-*tert*-butylphosphino)ferrocene (8.54 mg, 0.018 mmol), Pd(OAc)₂ (4.04 mg, 0.018 mmol), and aq Na₂CO₃ (2 M; 0.360 mL, 0.720 mmol) in 1,4-dioxane (1.5 mL). The mixture was heated in a sealed tube at 130 °C for 18 h and then cooled and purified by ion-exchange chromatography on acidic resin (2 g), eluting with MeOH and then with 1:1 CH₂Cl₂/7 M NH₃ in MeOH. The basic fractions were concentrated. Preparative HPLC, followed by preparative thin-layer chromatography, eluting with 1% NH₃ (aq) in 7% MeOH–CH₂Cl₂, gave **19** (2.90 mg, 4%). ¹H NMR (500 MHz, MeOH-*d*₄) δ 8.54 (dd, *J* = 0.9, 1.6 Hz, 1H), 8.14 (d, *J* = 1.0 Hz, 1H), 7.95 (dd, *J* = 1.6, 8.8 Hz, 1H), 7.81 (s, 1H), 7.63 (dt, *J* = 1.0, 8.9 Hz, 1H), 6.34 (s, 1H), 4.01 (dt, *J* = 3.7, 11.9 Hz, 2H), 3.84 (d, *J* = 10.4 Hz, 1H), 3.60 (td, *J* = 2.2, 11.6 Hz, 2H), 2.06 (ddt, *J* = 2.3, 4.6, 12.2 Hz, 2H), 1.69 (dtd, *J* = 4.3, 10.8, 13.2 Hz, 2H); ¹³C NMR (126 MHz, MeOH-*d*₄) δ 149.9, 143.4, 135.6, 134.5, 132.4, 131.1, 129.5, 127.6, 124.4, 122.6, 120.5, 111.3, 93.2, 67.4, 49.6 (2C), 33.3 (2C); LCMS (2 min) *t*_R = 1.35 min, *m/z* (ESI⁺) 369 (M + H⁺); HRMS *m/z* calcd for C₁₈H₁₈N₆O³⁵Cl (M + H) 369.1225, found 369.1216.

6-Chloro-3-(1*H*-indazol-5-yl)-*N*-(1-methylpiperidin-4-yl)imidazo[1,2-*b*]pyridazin-8-amine (20). Prepared from **3**, 1-methylpiperidin-4-amine, and 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1*H*-indazole using the method described for **19** to give **20** (11% over two steps). ¹H NMR (600 MHz, DMSO-*d*₆) δ 13.2 (s, 1H), 8.51 (s, 1H), 8.20 (s, 1H), 8.00 (s, 1H), 7.98 (s, 1H), 7.74 (br d, *J* = 8.5 Hz, 1H), 7.67 (br d, *J* = 8.8 Hz, 1H), 6.40 (s, 1H), 3.66 (br s, 1H), 2.95–2.93 (m, 2H), 2.33 (br s, 5H), 1.93–1.90 (m, 2H), 1.82–1.76 (m, 2H); ¹³C NMR (151 MHz, DMSO-*d*₆) δ 148.1, 143.3, 139.6, 134.6, 133.3, 129.4, 129.3, 125.9, 123.4, 121.2, 118.9, 110.9, 91.4, 55.4, 54.2, 45.4, 34.2, 31.8 (2C); LCMS (2 min) *t*_R = 0.94 min, *m/z* (ESI⁺) 382 (M + H⁺); HRMS *m/z* calcd for C₁₉H₂₁N₇³⁵Cl (M + H) 382.1547, found 382.1542.

6-Chloro-3-(1*H*-indazol-5-yl)-*N*-((1-methylpiperidin-4-yl)-methyl)imidazo[1,2-*b*]pyridazin-8-amine (21). Prepared from **3**, (1-methylpiperidin-4-yl)methanamine, and 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1*H*-indazole using the method described for **19** to give **21** (10% over two steps). ¹H NMR (500 MHz, MeOH-*d*₄) δ 8.53 (t, *J* = 0.7 Hz, 1H), 8.14 (d, *J* = 0.9 Hz, 1H), 7.94 (dd, *J* = 1.6 and 8.8 Hz, 1H), 7.78 (s, 1H), 7.62 (d, *J* = 8.8 Hz, 1H), 6.20 (s, 1H), 3.23 (d, *J* = 7.0 Hz, 2H), 2.94 (br d, *J* = 12 Hz, 2H), 2.31 (s, 3H), 2.10–2.05 (m, 2H), 1.86 (br d, *J* = 13 Hz, 2H), 1.74–1.70 (m, 1H), 1.42–1.34 (m, 2H); ¹³C NMR (126 MHz, Methanol-*d*₄) δ 148.4, 143.4, 139.6, 134.1, 133.0, 129.5, 128.1, 126.1, 122.9, 121.2, 118.9, 110.0, 91.4, 54.8, 44.8, 34.5, 29.2; LCMS (2 min) *t*_R = 1.09 min, *m/z* (ESI⁺) 396 (M + H⁺); HRMS *m/z* calcd for C₂₀H₂₃N₇³⁵Cl (M + H) 396.1703, found 396.1707.

(1*r*,4*r*)-*N*'-(6-Chloro-3-(1*H*-indazol-5-yl)imidazo[1,2-*b*]pyridazin-8-yl)cyclohexane-1,4-diamine (22). *tert*-Butyl ((1*r*,4*r*)-4-aminocyclohexyl)carbamate (0.929 g, 4.34 mmol) was added to a stirred solution of **3** (0.450 g, 1.45 mmol) in dimethylformamide (10 mL) at rt. The reaction was heated at 50 °C for 16 h, then cooled and partitioned between Na₂CO₃ aq and EtOAc. The organic layer was washed with brine, dried, and concentrated. Silica chromatography, eluting with 0–40% EtOAc–cyclohexane, gave *tert*-butyl ((1*r*,4*r*)-4-((3-bromo-6-chloroimidazo[1,2-*b*]pyridazin-8-yl)amino)cyclohexyl)carbamate (0.643 g, 100%). ¹H NMR (500 MHz, CDCl₃) δ 7.48 (s, 1H), 6.16 (s, 1H), 5.97 (d, *J* = 7.7 Hz, 1H), 4.08 (d, *J* = 13.4 Hz, 1H), 3.79 (s, 1H), 3.56 (s, 1H), 3.11 (dd, *J* = 13.1, 9.6, 3.4 Hz, 1H), 3.03 (dd, *J* = 13.3, 8.5 Hz, 1H), 2.16–2.09 (m, 1H), 1.84 (d, *J* = 14.3 Hz, 1H), 1.75–1.64 (m, 2H), 1.48 (s, 9H); LCMS (2 min) *t*_R = 1.57 min *m/z*, (ESI⁺) 446 (M + H⁺). A mixture of *tert*-butyl ((1*r*,4*r*)-4-((3-bromo-6-chloroimidazo[1,2-*b*]pyridazin-8-yl)amino)cyclohexyl)carbamate (0.100 g, 0.225 mmol), 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1*H*-indazole (0.055 g, 0.225 mmol), Pd(OAc)₂ (5.05 mg, 0.022 mmol), 1,1'-bis(di-*t*-butylphosphino)ferrocene (0.011 g, 0.022 mmol), and Na₂CO₃ aq (2 M; 0.45 mL, 0.900 mmol) in 1,4-dioxane (2 mL) was heated at 130 °C in a sealed tube for 24 h. The mixture was cooled, filtered through celite, and absorbed onto silica. Chromatography, eluting with 0–50% EtOAc–cyclohexane, gave *tert*-butyl ((1*r*,4*r*)-4-((6-chloro-3-(1*H*-indazol-5-yl)imidazo[1,2-*b*]-

pyridazin-8-yl)amino)cyclohexyl)carbamate (0.060 g, 55%). ¹H NMR (500 MHz, CDCl₃) δ 8.50 (s, 1H), 8.22 (s, 1H), 7.94 (d, *J* = 8.7 Hz, 1H), 7.74 (s, 1H), 7.61 (d, *J* = 8.8 Hz, 1H), 6.18 (d, *J* = 8.0 Hz, 1H), 6.04 (d, *J* = 7.0 Hz, 1H), 4.54–4.47 (m, 1H), 3.54 (s, 1H), 3.47–3.37 (m, 1H), 2.52–2.12 (m, 4H), 1.48 (s, 9H), 1.37–1.24 (m, 4H); LCMS (2 min) *t*_R = 1.56 min *m/z*, (ESI⁺) 482 (M + H⁺). *tert*-Butyl ((1*r*,4*r*)-4-((6-chloro-3-(1*H*-indazol-5-yl)imidazo[1,2-*b*]pyridazin-8-yl)amino)cyclohexyl)carbamate (30 mg, 0.062 mmol) was dissolved in HCl–1,4-dioxane (4 M; 1 mL) and stirred at rt for 2 h. The mixture was concentrated. Ion-exchange chromatography on acidic resin, eluting with 2 M NH₃–MeOH, followed by preparative HPLC gave **22** (24 mg, 99%). ¹H NMR (500 MHz, DMSO-*d*₆) δ 8.50 (t, *J* = 1.2 Hz, 1H), 8.19 (d, *J* = 1.0 Hz, 1H), 7.96–7.89 (m, 2H), 7.69–7.62 (m, 1H), 7.55 (s, 1H), 6.34 (s, 1H), 3.52 (s, 1H), 3.17 (br s, 3H), 2.57 (tt, *J* = 10.5, 3.6 Hz, 1H), 1.99–1.71 (m, 4H), 1.50 (q, *J* = 13.3, 12.7 Hz, 2H), 1.25–1.15 (m, 2H); ¹³C NMR (126 MHz, DMSO-*d*₆) δ 165.6, 147.7, 142.78, 139.3, 134.0, 132.8, 128.9, 125.4, 122.9, 120.8, 118.4, 110.6, 90.9, 49.7, 48.5, 29.5 (2C), 29.3 (2C); LCMS (2 min) *t*_R = 1.11 min, *m/z*, (ESI⁺) 382 (M + H⁺); HRMS *m/z* calcd for C₁₉H₂₀N₇³⁵Cl (M + H) 382.1547, found 382.1538.

(1*r*,4*r*)-*N*'-(6-Chloro-3-(1*H*-indazol-5-yl)imidazo[1,2-*b*]pyridazin-8-yl)-*N*'-methylcyclohexane-1,4-diamine (23). LiAlH₄ in THF (1 M; 25 mL, 25.0 mmol) was added to a solution of *tert*-butyl ((1*r*,4*r*)-4-aminocyclohexyl)carbamate (1.30 g, 6.07 mmol) in THF (5 mL) at 0 °C. The mixture was heated to reflux for 4 h, forming a thick white suspension. The reaction was cooled, diluted with Et₂O (80 mL), and water (0.95 mL) was slowly added dropwise, followed by 15% w/v NaOH aq (0.95 mL). After stirring for 1 h, water (2.85 mL) was added dropwise. The mixture was filtered through celite, washed with Et₂O, and the filtrate was concentrated to give crude (1*r*,4*r*)-*N*'-methylcyclohexane-1,4-diamine (0.597 g). A solution of the crude amine, Et₃N (1.3 mL, 9.31 mmol), and ethyl 1,3-dioxoisindoline-2-carboxylate (0.928 g, 4.23 mmol) in CH₂Cl₂ (42 mL) was stirred at rt for 15 h. Saturated (NH₄)₂CO₃ aq (50 mL) was added, and the mixture was extracted with CH₂Cl₂ (3 × 30 mL). The combined organic layers were dried and concentrated to give crude 2-((1*r*,4*r*)-4-(methylamino)cyclohexyl)isindoline-1,3-dione (0.99 g). A mixture of the crude amine, **3** (0.918 g, 2.95 mmol), and Et₃N (0.82 mL, 5.90 mmol) in 1,4-dioxane (3.7 mL) and DMSO (3.7 mL) was heated at 100 °C for 21 h. The mixture was cooled and diluted with CH₂Cl₂ (15 mL). The solid was collected and washed with dichloromethane (DCM, 5 mL) to give 2-((1*r*,4*r*)-4-((3-bromo-6-chloroimidazo[1,2-*b*]pyridazin-8-yl)(methyl)amino)cyclohexyl)isindoline-1,3-dione (1.06 g, 52% over three steps). ¹H NMR (500 MHz, DMSO-*d*₆) δ 7.88–7.82 (m, 4H), 7.80 (s, 1H), 6.26 (s, 1H), 5.76 (br s, 1H), 4.18–4.08 (m, 1H), 3.10 (br s, 3H), 2.39–2.25 (m, 2H), 1.97–1.77 (m, 6H); LCMS (4 min) *t*_R = 3.53 min, *m/z* (ESI⁺) 490 (M + H⁺). A mixture of 2-((1*r*,4*r*)-4-((3-bromo-6-chloroimidazo[1,2-*b*]pyridazin-8-yl)(methyl)amino)cyclohexyl)-isindoline-1,3-dione (0.210 g, 0.430 mmol), 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1*H*-indazole (0.126 g, 0.516 mmol), Pd(OAc)₂ (9.6 mg, 0.043 mmol), 1,1'-bis(di-*tert*-butylphosphino)ferrocene (0.020 g, 0.043 mmol), and Na₂CO₃ aq (2 M; 0.86 mL, 1.72 mmol) in 1,4-dioxane (2.1 mL) was heated at 130 °C for 21 h. The reaction mixture was cooled and NH₂NH₂·H₂O (0.5 mL) was added. The mixture was heated at 100 °C for 48 h. The mixture was cooled and purified by ion-exchange chromatography on acidic resin, eluting with 2 M NH₃ in MeOH. Reversed-phase silica chromatography, eluting with 10–90% MeOH–water containing 0.1% HCO₂H, followed by normal phase chromatography, eluting with 2–20% EtOH–CH₂Cl₂, gave **23** (0.058 g, 34%). ¹H NMR (600 MHz, DMSO-*d*₆) δ 13.20 (s, 1H), 8.47–8.44 (m, 1H), 8.20 (d, *J* = 0.9 Hz, 1H), 7.96 (s, 1H), 7.90 (dd, *J* = 8.7, 1.6 Hz, 1H), 7.67 (d, *J* = 8.7 Hz, 1H), 6.19 (s, 1H), 5.70 (br s, 1H), 3.07 (br s, 3H), 2.57 (tt, *J* = 11.1, 3.9 Hz, 1H), 1.88–1.81 (m, 2H), 1.76–1.70 (m, 4H), 1.62 (br s, 2H), 1.32–1.18 (m, 2H); ¹³C NMR (151 MHz, DMSO-*d*₆) δ 147.6, 145.1, 139.7, 134.5, 133.7, 129.3, 128.9, 126.3, 123.3, 121.2, 119.4, 110.9, 94.1, 57.9, 50.0, 35.8 (2C), 32.7, 28.9 (2C); LCMS (4 min) *t*_R = 2.26 min, *m/z* (ESI⁺) 396 (M + H⁺); HRMS *m/z* calcd for C₂₀H₂₂N₇³⁵Cl (M + H) 396.1703, found 396.1700.

N-(*trans*-4-((6-Chloro-3-(1*H*-indazol-5-yl)imidazo[1,2-*b*]pyridazin-8-yl)amino)cyclohexyl)acetamide (**24**). Prepared from 3, *N*-((1*r,4r*)-4-aminocyclohexyl)acetamide, and 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1*H*-indazole using the methods described for **19**, except that the first step was conducted at 50 °C, to give **24** (35% over two steps). ¹H NMR (500 MHz, DMSO-*d*₆) δ 13.18 (s, 1H), 8.50 (dt, *J* = 0.8, 1.6 Hz, 1H), 8.19 (t, *J* = 1.3 Hz, 1H), 7.96–7.90 (m, 2H), 7.80 (d, *J* = 7.7 Hz, 1H), 7.65 (dt, *J* = 0.9, 8.7 Hz, 1H), 7.61 (d, *J* = 8.8 Hz, 1H), 6.42 (s, 1H), 3.60 (s, 1H), 3.50 (dt, *J* = 4.1, 8.1, 11.9 Hz, 1H), 1.93 (t, *J* = 8.2 Hz, 2H), 1.79 (s, 5H), 1.56 (d, *J* = 12.8 Hz, 2H), 1.41–1.27 (m, 2H); ¹³C NMR (126 MHz, DMSO-*d*₆) δ 168.3, 147.7, 142.8, 139.1, 134.2, 132.9, 128.9, 128.8, 125.5, 122.9, 120.8, 118.4, 110.4, 90.7, 50.1, 47.2, 30.9 (2C), 30.3 (2C), 22.8; LCMS (2 min), *t*_R = 1.32 min, *m/z* (ESI⁺) 424 (M + H⁺); HRMS *m/z* calcd for C₂₁H₂₃N₇O³⁵Cl (M + H) 424.1647, found 424.1635.

6-Chloro-3-(1*H*-indazol-5-yl)-*N*-(*trans*-4-morpholinocyclohexyl)imidazo[1,2-*b*]pyridazin-8-amine, Formate Salt (**25**). Prepared from 3, (1*r,4r*)-4-morpholinocyclohexan-1-amine, and 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1*H*-indazole using the methods described for **19**, except that the first step was conducted at 50 °C, to give **25** (4% over two steps), isolated as the formate salt from preparative HPLC. ¹H NMR (500 MHz, MeOH-*d*₄) δ 8.56–8.52 (m, 1H), 8.36 (s, 1H), 8.14 (d, *J* = 1.0 Hz, 1H), 7.94 (dd, *J* = 1.6, 8.8 Hz, 1H), 7.79 (s, 1H, formate), 7.63 (d, *J* = 8.6 Hz, 1H), 6.26 (s, 1H), 3.88 (t, *J* = 4.7 Hz, 4H), 3.55–3.51 (m, 1H), 3.13 (t, *J* = 4.6 Hz, 4H), 3.00 (ddd, *J* = 3.3, 8.4, 12.1 Hz, 1H), 2.28–2.15 (m, 4H), 1.63 (qd, *J* = 3.2, 12.6 Hz, 2H), 1.46 (qd, *J* = 2.9, 13.1 Hz, 2H); ¹³C NMR (126 MHz, MeOH-*d*₄) δ 167.8 (formate), 149.8, 143.5, 141.1, 135.5, 134.4, 131.0, 129.6, 127.5, 124.4, 122.6, 120.4, 111.4, 93.1, 65.9 (2C), 65.4, 51.4, 50.4 (2C), 31.4 (2C), 26.6 (2C); LCMS (2 min), *t*_R = 1.00 min, *m/z* (ESI⁺) 452 (M + H⁺); HRMS *m/z* calcd for C₂₃H₂₇N₇O³⁵Cl (M + H) 452.1966, found 452.1961.

2-(((1*r,4r*)-4-((6-Chloro-3-(1*H*-indazol-5-yl)imidazo[1,2-*b*]pyridazin-8-yl)amino)cyclohexyl)amino)-1-morpholinoethan-1-one (**26**). A solution of 2-chloro-1-morpholinoethanone (0.66 mL, 5.05 mmol), *tert*-butyl ((1*r,4r*)-4-aminocyclohexyl)carbamate (902 mg, 4.21 mmol), and Et₃N (2.1 mL, 15.1 mmol) in CH₂Cl₂ (35 mL) was stirred at rt for 20 h. The mixture was partitioned between water (50 mL) and CH₂Cl₂ (30 mL × 2). The combined organic layers were dried and concentrated. The resulting crude material was dissolved in MeOH (42 mL), and HCl in 1,4-dioxane (4 M; 42 mL, 168 mmol) was added. After 2 h at rt, the mixture was concentrated and purified by ion-exchange chromatography on acidic resin, eluting with 2 M NH₃ in MeOH, to give 2-(((1*r,4r*)-4-aminocyclohexyl)amino)-1-morpholinoethan-1-one (0.375 g, 37%). ¹H NMR (500 MHz, CDCl₃) δ 3.71–3.59 (m, 7H), 3.49–3.36 (m, 4H), 2.72–2.58 (m, 3H), 2.42–2.33 (m, 1H), 1.94–1.78 (m, 4H), 1.24–1.04 (m, 4H). A sample of the material (0.370 g, 1.55 mmol), 3 (0.440 g, 1.41 mmol), and Et₃N (0.39 mL, 2.83 mmol) in 1,4-dioxane (1.8 mL) and DMSO (1.8 mL) was heated at 50 °C for 23 h. The mixture was cooled and purified by ion-exchange chromatography on acidic resin, eluting with 2 M NH₃ in MeOH, and then by silica chromatography, eluting with 2–20% EtOH–CH₂Cl₂, to give 2-(((1*r,4r*)-4-((3-bromo-6-chloroimidazo[1,2-*b*]pyridazin-8-yl)amino)cyclohexyl)amino)-1-morpholinoethan-1-one (0.38 g, 58%). ¹H NMR (500 MHz, CDCl₃) δ 7.44 (s, 1H), 6.04 (s, 1H), 5.80 (d, *J* = 8.1 Hz, 1H), 3.75–3.62 (m, 7H), 3.47 (s, 2H), 3.43–3.40 (m, 3H), 2.56–2.47 (m, 1H), 2.23–2.15 (m, 2H), 2.10–2.01 (m, 2H), 1.43–1.29 (m, 4H); LCMS (2 min) *t*_R = 0.97 min, *m/z* (ESI⁺) 473 (M + H⁺). A sample of the material (0.365 g, 0.774 mmol), 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1*H*-indazole (0.227 g, 0.928 mmol), Pd(OAc)₂ (17.0 mg, 0.077 mmol), 1,1'-bis(di-*tert*-butylphosphino)ferrocene (37.0 mg, 0.077 mmol), and Na₂CO₃ aq (2 M; 1.55 mL, 3.09 mmol) were mixed in 1,4-dioxane (3.9 mL) and heated at 135 °C for 19 h. The mixture was cooled and purified by ion-exchange chromatography on acidic resin, eluting with 2 M NH₃ in MeOH, then by silica chromatography, eluting with 2–20% MeOH–CH₂Cl₂, and then by reversed-phase chromatography, eluting with 10–70% MeOH–water with 0.1% formic acid, to give **26** (0.069 g, 18%). ¹H NMR (500 MHz, MeOH-*d*₄) δ 8.49 (dd, *J* = 1.6, 0.9 Hz, 1H), 8.11 (d, *J* = 1.0 Hz,

1H), 7.89 (dd, *J* = 8.8, 1.6 Hz, 1H), 7.72 (s, 1H), 7.59 (d, *J* = 8.7 Hz, 1H), 6.17 (s, 1H), 3.67–3.63 (m, 4H), 3.59–3.55 (m, 2H), 3.46 (s, 2H), 3.45–3.42 (m, 3H), 2.50–2.41 (m, 1H), 2.13–2.06 (m, 2H), 2.02–1.96 (m, 2H), 1.40–1.24 (m, 4H); ¹³C NMR (126 MHz, MeOH-*d*₄) δ 171.2, 149.8, 143.5, 141.0, 135.5, 134.4, 130.9, 129.4, 127.5, 124.4, 122.6, 120.3, 111.3, 92.9, 67.7, 67.6, 57.2, 52.2, 48.0, 46.1, 43.4, 32.0 (2C), 31.6 (2C); LCMS (2 min) *t*_R = 1.05 min, *m/z* (ESI⁺) 509 (M + H⁺); HRMS *m/z* calcd for C₂₅H₃₀N₈O₂³⁵Cl (M + H) 509.2180, found 509.2187.

6-Chloro-3-(2-(phenylamino)-1*H*-benzo[*d*]imidazol-5-yl)-*N*-(*tetrahydro-2H*-pyran-4-yl)imidazo[1,2-*b*]pyridazin-8-amine (**27**). Prepared from **4**, tetrahydro-2*H*-pyran-4-amine, and **13** using the method described for **19** to give **27** (14% over two steps). ¹H NMR (500 MHz, DMSO-*d*₆) δ 11.13 and 11.01 (2 × s, 1H, NH); 9.53 and 9.50 (2 × s, 1H, NH), 8.06 (dd, *J* = 1.7, 12.9 Hz, 1H), 7.87 (d, *J* = 11.0 Hz, 1H), 7.82–7.75 (m, 2H), 7.71 (dd, *J* = 6.7, 8.7 Hz, 1H), 7.64–7.58 (m, 1H), 7.41 (dd, *J* = 8.3, 28.4 Hz, 1H), 7.36–7.29 (m, 2H), 6.94 (tt, *J* = 1.2, 7.3 Hz, 1H), 6.43 (s, 1H), 3.83–3.96 (m, 2H), 3.45 (td, *J* = 2.0, 11.7 Hz, 2H), 3.33 (s, 1H), 1.92–1.79 (m, 2H), 1.78–1.64 (m, 2H); ¹³C NMR (126 MHz, DMSO-*d*₆) δ 151.4, 151.2, 147.5, 143.2, 143.1, 142.6, 140.7, 132.9, 132.6, 129.7, 128.8 (2C), 128.5, 120.9, 120.7, 120.0, 117.2 (2C), 117.1, 115.8, 114.2, 109.5, 107.7, 90.6, 66.0 (2C), 48.2, 31.8 (2C); LCMS (4 min) *t*_R = 2.60 min, *m/z* (ESI⁺) 460 (M + H⁺); HRMS *m/z* calcd for C₂₄H₂₂N₇O³⁵Cl (M + H) 460.1653, found 460.1651.

6-Chloro-*N*-(1-methylpiperidin-4-yl)-3-(2-(phenylamino)-1*H*-benzo[*d*]imidazol-5-yl)imidazo[1,2-*b*]pyridazin-8-amine (**28**). Prepared from 3, 1-methylpiperidin-4-amine, and **13** using the method described for **19** to give **28** (5% over two steps). ¹H NMR (500 MHz, DMSO-*d*₆) δ 11.14 and 11.02 (2 × s, 1H, NH), 9.54 and 9.51 (2 × s, 1H, NH), 8.11–8.10 (m, 1H), 7.86 (d, *J* = 10.6 Hz, 1H), 7.78 (d, *J* = 7.9 Hz, 2H), 7.65–7.57 (m, 2H), 7.41 (dd, *J* = 8.3, 28.5 Hz, 1H), 7.36–7.28 (m, 2H), 6.97–6.90 (m, 1H), 6.35 (s, 1H), 3.57 (d, *J* = 2.3 Hz, 1H), 2.80 (d, *J* = 11.1 Hz, 2H), 2.21 (s, 3H), 2.08 (t, *J* = 11.7 Hz, 2H), 1.86 (d, *J* = 12.2 Hz, 2H), 1.80–1.67 (m, 2H); ¹³C NMR (126 MHz, DMSO-*d*₆) δ 151.4, 151.2, 147.5, 143.2, 143.1, 142.8, 140.7, 132.9, 132.6, 129.7, 128.8 (2C), 128.4, 120.9, 120.7, 119.9, 119.0, 117.2 (2C), 117.1, 115.8, 114.2, 109.5, 107.7, 90.6, 54.1 (2C), 48.8, 45.8, 30.7 (2C); LCMS (2 min) *t*_R = 0.86 min, *m/z* (ESI⁺) 473 (M + H⁺); HRMS *m/z* calcd for C₂₅H₂₅N₈³⁵Cl (M + H) 473.1969, found 473.1961.

6-Chloro-*N*-((1-methylpiperidin-4-yl)methyl)-3-(2-(phenylamino)-1*H*-benzo[*d*]imidazol-5-yl)imidazo[1,2-*b*]pyridazin-8-amine (**29**). Prepared from 3, (1-methylpiperidin-4-yl)methanamine, and **13** using the method described for **19** to give **29** (13% over two steps). ¹H NMR (500 MHz, DMSO-*d*₆) δ 11.19 and 11.07 (2 × s, 1H, NH), 9.57 and 9.54 (2 × s, 1H, NH), 8.05 (d, *J* = 13.4 Hz, 1H), 7.93 (s, 1H), 7.85 (d, *J* = 9.2 Hz, 1H), 7.79 (d, *J* = 8.0 Hz, 2H), 7.61 (d, *J* = 8.2 Hz, 1H), 7.40 (dd, *J* = 8.2, 9.4 Hz, 1H), 7.32 (t, *J* = 7.8 Hz, 2H), 6.93 (tt, *J* = 1.2, 7.3 Hz, 1H), 6.30 (s, 1H), 3.23 (s, 2H), 2.79 (d, *J* = 11.2 Hz, 2H), 2.17 (s, 3H), 1.96–1.81 (m, 2H), 1.74–1.60 (m, 3H), 1.32–1.16 (m, 2H); ¹³C NMR (126 MHz, DMSO-*d*₆) δ 151.4, 151.3, 147.5, 143.9, 143.2, 143.1, 140.8, 132.9, 132.6, 129.7, 128.8 (2C), 128.4, 120.7, 119.9, 119.0, 117.2 (2C), 115.8, 114.2, 109.5, 107.7, 90.3, 54.9 (2C), 47.2, 45.9, 34.2, 29.4 (2C); LCMS (2 min) *t*_R = 1.03 min, *m/z* (ESI⁺) 487 (M + H⁺); HRMS *m/z* calcd for C₂₆H₂₇N₈³⁵Cl (M + H) 487.2125, found 487.2130.

6-Chloro-3-(7-fluoro-2-(phenylamino)-1*H*-benzo[*d*]imidazol-5-yl)-*N*-(1-methylpiperidin-4-yl)methylimidazo[1,2-*b*]pyridazin-8-amine (**30**). Prepared from 5-bromo-3-fluorobenzene-1,2-diamine and 3-bromo-6-chloro-*N*-((1-methylpiperidin-4-yl)methyl)imidazo[1,2-*b*]pyridazin-8-amine using the method described for **31** to give **30** (5% over 4 steps). ¹H NMR (500 MHz, DMSO-*d*₆) δ 11.67 (s, 1H), 9.82 (s, 1H), 7.97 (t, *J* = 6.5 Hz, 1H), 7.94 (s, 2H), 7.83–7.72 (m, 2H), 7.54 (d, *J* = 12.2 Hz, 1H), 7.39–7.29 (m, 2H), 6.96 (tt, *J* = 1.2, 7.3 Hz, 1H), 6.33 (s, 1H), 3.24 (s, 2H), 2.80 (d, *J* = 11.2 Hz, 2H), 1.88 (t, *J* = 11.5 Hz, 2H), 2.18 (s, 3H), 1.77–1.61 (m, 3H), 1.32–1.17 (m, 2H); ¹³C NMR (151 MHz, DMSO-*d*₆) δ 152.0, 148.1, 144.3, 140.9, 133.4, 129.5, 129.3 (2C), 128.9, 121.5, 120.8, 117.9 (2C), 105.8 (d, *J*_{C-F} = 16.6 Hz), 104.5, 91.0, 55.5 (2C), 47.8, 46.6,

34.8, 30.0 (2C) (3 quaternary C not observed); LCMS (2 min) t_R = 1.13 min, m/z (ESI⁺) 505 (M + H⁺); HRMS m/z calcd for C₂₆H₂₆N₈F³⁵Cl (M + H) 505.2031, found 505.2036.

6-Chloro-3-(6-fluoro-2-(phenylamino)-1H-benzo[d]imidazol-5-yl)-N-((1-methylpiperidin-4-yl)methyl)imidazo[1,2-b]pyridazin-8-amine (31). A mixture of (1-methylpiperidin-4-yl)methanamine (1.24 g, 9.64 mmol), **3** (2.00 g, 6.42 mmol), and Et₃N (1.79 mL, 12.9 mmol) in 1,4-dioxane (4 mL) and DMSO (4 mL) was stirred at 50 °C for 18 h. The mixture was cooled, diluted with EtOAc, and the organic layer was washed sequentially with water and brine. The organic layer was dried and concentrated. Ion-exchange chromatography on acidic resin, eluting with 2 M NH₃ in MeOH, followed by silica chromatography, eluting with 0–5% MeOH–CH₂Cl₂ and then with 5–10% MeOH–DCM + 0.2 M NH₃, gave 3-bromo-6-chloro-N-((1-methylpiperidin-4-yl)methyl)imidazo[1,2-b]pyridazin-8-amine (2.00 g, 87%), which was used directly in subsequent steps. LCMS (2 min) t_R = 0.84 min, m/z (ESI⁺) 360 (M + H⁺). Separately, isothiocyanatobenzene (1.22 mL, 10.2 mmol) and EDC (3.37 g, 17.5 mmol) were added to a stirred solution of 4-bromo-5-fluorobenzene-1,2-diamine (2.00 g, 9.75 mmol) in dry THF (100 mL) at rt. The mixture was heated at 50 °C for 4 h, cooled, and concentrated. The residue was partitioned between water (100 mL) and EtOAc (100 mL). The organic layer was washed with brine (100 mL), dried, and concentrated. Ion-exchange chromatography on acidic resin, eluting with MeOH, gave 5-bromo-6-fluoro-N-phenyl-1H-benzo[d]imidazol-2-amine that was used directly in the next step (2.53 g, 85%). ¹H NMR (500 MHz, DMSO-*d*₆) δ 11.10 and 10.99 (2 × s, 1H, NH), 9.61 and 9.58 (2 × s, 1H, NH), 7.74–7.60 (m, 2H), 7.60–7.45 (m, 1H), 7.35–7.23 (m, 3H), 6.95 (t, *J* = 7.3 Hz, 1H); ¹³C NMR (126 MHz, DMSO-*d*₆) δ 154.6, 152.5, 152.0, 143.4, 140.3, 130.4, 128.8 (2C), 121.15, 121.1, 118.5, 117.4 (2C), 117.3, 112.3, 103.2 (d, *J* = 26.0 Hz), 97.8 (d, *J* = 26.0 Hz), (1 quaternary C not observed); LCMS (2 min) t_R = 1.01 min, m/z (ESI⁺) 306 (M + H⁺); HRMS m/z calcd for C₁₃H₉N₃F⁷⁹Br (M + H) 306.0042, found 306.0047. A mixture of 5-bromo-6-fluoro-N-phenyl-1H-benzo[d]imidazol-2-amine (2.53 g, 8.26 mmol), (Boc)₂O (4.50 g, 20.7 mmol), and DMAP (0.20 g, 1.65 mmol) in THF (80 mL) was stirred at rt for 16 h. The mixture was concentrated, and the residue was partitioned between EtOAc (100 mL) and water (100 mL). The organic layer was washed with brine (100 mL), dried, and concentrated. Silica chromatography, eluting with 0–10% EtOAc–cyclohexane, gave the product as a mixture of three different di-Boc-protected positional isomers (1.94 g), which was used as such in the next step. LCMS (2 min) t_R = 1.68, 1.79, and 1.92 min, m/z (ESI⁺) 506 (M + H⁺). This material (1.94 g) was stirred at rt in 1,4-dioxane (42 mL), and bis(pinacolato)diboron (1.17 g, 4.59 mmol), PdCl₂dppf (0.28 g, 0.38 mmol), and KOAc (0.75 g, 7.65 mmol) were added. The mixture was heated at 120 °C for 24 h, then cooled and filtered through celite. The filtrate was concentrated and dissolved in THF (80 mL). DMAP (0.093 g, 0.77 mmol) and (Boc)₂O (1.67 g, 7.66 mmol) were added, and the mixture was stirred for 6 h at rt. Solvent was removed by evaporation, and the residue was partitioned between water (100 mL) and EtOAc (100 mL). The organic layer was washed with brine (100 mL), dried, and concentrated. Silica chromatography, eluting with 0–50% EtOAc–cyclohexane, gave the product as a mixture of three different di-Boc-protected positional isomers (1.08 g), which was used as such in the next step. LCMS (2 min) t_R = 1.67, 1.78, and 1.81 min, m/z (ESI⁺) 554 (M + H⁺). A mixture of this material (1.08 g), 3-bromo-6-chloro-N-((1-methylpiperidin-4-yl)methyl)imidazo[1,2-b]pyridazin-8-amine (0.63 g, 1.76 mmol) and Na₂CO₃ aq (2 M; 3.51 mL, 7.03 mmol) in dry 1,4-dioxane (18 mL) was purged with N₂ for 10 min. Pd(OAc)₂ (0.079 g, 0.35 mmol) and 1,1'-bis(di-*tert*-butylphosphino)ferrocene (0.17 g, 0.35 mmol) were added and the tube was sealed and stirred at 135 °C for 15 h. The mixture was cooled, filtered through celite pad, and concentrated. The residue was purified by silica chromatography, eluting with 0–5% MeOH–CH₂Cl₂ and then with 5–10% MeOH–CH₂Cl₂ + 1% 0.2 M NH₃ aq, to give **31** (100 mg, 3% over three steps). ¹H NMR (500 MHz, DMSO-*d*₆) δ 11.14 (s, 1H), 9.62 (s, 1H), 8.00 (d, *J* = 6.5 Hz, 1H), 7.82 (d, *J* = 6.6 Hz, 1H), 7.79–7.74 (m, 2H), 7.70 (d, *J* = 2.5 Hz, 1H), 7.35–7.31 (m, 2H), 7.28 (d, *J* =

11.1 Hz, 1H), 6.98–6.92 (m, 1H), 6.31 (s, 1H), 3.23 (s, 2H), 2.75 (d, *J* = 10.8 Hz, 2H), 2.13 (s, 3H), 1.87–1.73 (m, 2H), 1.73–1.59 (m, 3H), 1.31–1.16 (m, 2H); ¹³C NMR (151 MHz, DMSO-*d*₆) δ 154.1 (d, *J*_{C–F} = 257.2 Hz), 148.1, 144.3, 140.9, 132.9, 131.0, 129.8, 129.3 (2C), 124.5, 121.5, 117.9 (2C), 110.0, 102.8, 91.1, 55.5 (2C), 47.8, 46.6, 34.8, 30.1 (2C) (3 quaternary C not observed); LCMS (2 min) t_R = 0.91 min, m/z (ESI⁺) 505 (M + H⁺); ESI m/z calcd for C₂₆H₂₆N₈F³⁵Cl (M + H) 505.2031, found 505.2036.

6-Chloro-3-(4-fluoro-2-(phenylamino)-1H-benzo[d]imidazol-5-yl)-N-((1-methylpiperidin-4-yl)methyl)imidazo[1,2-b]pyridazin-8-amine (32). Prepared from 4-bromo-3-fluorobenzene-1,2-diamine and 3-bromo-6-chloro-N-((1-methylpiperidin-4-yl)methyl)imidazo[1,2-b]pyridazin-8-amine using the method described for **31** to give **32** (2% over four steps). ¹H NMR (500 MHz, DMSO-*d*₆) δ 11.38 (s, 1H), 9.62 (s, 1H), 7.99 (t, *J* = 6.3 Hz, 1H), 7.81–7.74 (m, 2H), 7.69 (d, *J* = 1.4 Hz, 1H), 7.38 (t, *J* = 7.3 Hz, 1H), 7.36–7.32 (m, 2H), 7.25 (d, *J* = 8.2 Hz, 1H), 6.96 (tt, *J* = 1.2, 7.3 Hz, 1H), 6.29 (s, 1H), 3.23 (s, 2H), 2.79–2.68 (m, 2H), 2.13 (s, 3H), 1.86–1.74 (m, 2H), 1.73–1.60 (m, 3H), 1.30–1.16 (m, 2H); ¹³C NMR (151 MHz, DMSO-*d*₆) δ 151.9, 148.1, 144.3, 140.9, 133.0, 130.7, 129.3 (2C), 124.8, 122.0, 121.4, 117.8 (2C), 107.9, 106.2, 91.1, 55.4 (2C), 47.7, 46.4, 34.7, 29.9 (2C) (3 quaternary C not observed); LCMS (2 min) t_R = 1.14 min, m/z (ESI⁺) 505 (M + H⁺); HRMS m/z calcd for C₂₆H₂₆N₈F³⁵Cl (M + H) 505.2031, found 505.2013.

■ ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.jmedchem.8b01721.

Mass spectrometry characterization of IRE1α proteins; schematic of the fluorescence-labeled stem-loop RNA used to measure inhibition of IRE1α RNase activity; selectivity of compounds **26** and **31** for IRE1α vs IRE1β kinase inhibition; kinase selectivity profiles of compounds **2**, **26**, and **31**; chemical structure and IRE1α inhibition data for **33**; crystal structure of **33**-IRE1α; model of **26** bound to IRE1α; microscopic images showing inhibition of stress-induced GFP-IRE1α foci formation in HEK293 cells by **26** and **31**; titrations of inhibition of stress-induced splicing of XBP1-Luc reporter mRNA in HEK293 cells by **26** and **31**; titrations of inhibition of stress-induced XBP1s mRNA expression in NCI-H929 cells by **26** and **31**; quantification of inhibition of pS724 IRE1α relative to total IRE1α using capillary electrophoresis immunoassay in H929 cells by **26** and **31**; microscopic images showing inhibition of stress-induced expression of XBP1s in NCI-H929 cells by **26** and **31**; titrations of the inhibition of IRE1α autophosphorylation, IRE1α ATP-site binding, and IRE1α RNase by compounds **2**, **26**, and **31** in in vitro assays; selectivity profiles of **2**, **26**, and **31** tested against 455 human kinases at 1000 nM; HPLC purities of compounds **2**, **5–12**, and **19–33**; experimental method for the generation of an HEK293TN XBP1 luciferase reporter cell line; experimental methods to determine inhibition of an XBP1 luciferase reporter in HEK293TN cells and assess compound cytotoxicity to HEK293TN cells; experimental method for the quantification of XBP1s expression in NCI-H929 cells by immunofluorescence; experimental method for the quantification of XBP1s and DNAJB9 mRNA expression in NCI-H929 cells by qPCR; experimental method for the quantification of the inhibition of IRE1α-GFP oligomerization in T-Rex293-IRE1-3F6HGFP cells;

experimental methods for the quantification of total IRE1 α and pIRE1 α expression in NCI-H929 cells; experimental method for the determination of the crystal structure of 33-IRE1 α ; summary of crystallographic data for 2-IRE1 α and 33-IRE1 α ; experimental methods for the synthesis of 33; copies of ^1H and ^{13}C NMR spectra of compounds 2, 5–12, and 19–33; copies of HPLC traces for compounds 2, 5–12, and 19–33; and molecular formula strings for compounds 2, 5–12, and 19–33 (PDF)

Molecular formula strings (CSV)

Accession Codes

PDB ID Codes: 2-IRE1 α , 6HX1; 33-IRE1 α , 6HV0.

AUTHOR INFORMATION

Corresponding Author

*E-mail: ian.collins@icr.ac.uk.

ORCID

Thomas P. Matthews: 0000-0002-4765-7734

Ngai Yi Mok: 0000-0002-2827-3735

Richard Bayliss: 0000-0003-0604-2773

Ian Collins: 0000-0002-8143-8498

Present Address

¹UAMS Myeloma Institute, 4018 W Capitol Avenue, Little Rock, Arkansas 72205, United States (F.E.D.).

Author Contributions

The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.

Notes

The authors declare the following competing financial interest(s): All authors who are, or have been, employed by The Institute of Cancer Research are subject to a Rewards to Inventors Scheme which may reward contributors to a program that is subsequently licensed. The Institute of Cancer Research has a commercial interest in the development of inhibitors of IRE1- α .

ACKNOWLEDGMENTS

This work was supported by Cancer Research UK grants C309/A11566 (to the Cancer Therapeutics Unit, ICR), C20826/A12 (to F.E.D.), C24461/A13231 and C24461/A12772 (to R.B.), Janssen Biotech Inc., and The Institute of Cancer Research. The authors thank Dr. Sebastian Naud for the original synthesis of 2; Dr. Amin Mirza, Dr. Maggie Liu, and Meirion Richards for assistance in the structural characterization of compounds; Prof. Peter Walter for providing GFP-IRE1 α HEK293 cells; Miri Jwa for details of the GFP-IRE1 α oligomerization assay; Dr. Martin Augustin (Proteros Biostructures GmbH) for crystallography data; and Drs. Olivia Rossanese, Julian Blagg, Matthias Versele, and Ian Stansfield for helpful discussions and their interest in this work.

REFERENCES

- (1) Hetz, C.; Papa, F. R. The unfolded protein response and cell fate control. *Mol. Cell* **2018**, *69*, 169–181.
- (2) Corazzari, M.; Gagliardi, M.; Fimia, G. M.; Piacentini, M. Endoplasmic reticulum stress, unfolded protein response and cancer cell fate. *Front. Oncol.* **2017**, *7*, 78.
- (3) Lee, K. P.; Dey, M.; Neculai, D.; Cao, C.; Dever, T. E.; Sicheri, F. Structure of the dual enzyme Ire1 reveals the basis for catalysis and regulation in nonconventional RNA splicing. *Cell* **2008**, *132*, 89–100.

- (4) Korennykh, A. V.; Egea, P. F.; Korostelev, A. A.; Finer-Moore, J.; Zhang, C.; Shokat, K. M.; Stroud, R. M.; Walter, P. The unfolded protein response signals through high-order assembly of Ire1. *Nature* **2009**, *457*, 687–693.

- (5) Ali, M. M.; Bagratuni, T.; Davenport, E. L.; Nowak, P. R.; Silva-Santisteban, M. C.; Hardcastle, A.; McAndrews, C.; Rowlands, M. G.; Morgan, G. J.; Aherne, W.; Collins, I.; Davies, F. E.; Pearl, L. H. Structure of the Ire1 autophosphorylation complex and implications for the unfolded protein response. *EMBO J.* **2011**, *30*, 894–905.

- (6) Joshi, A.; Newbatt, Y.; McAndrew, P. C.; Stubbs, M.; Burke, R.; Richards, M. W.; Bhatia, C.; Caldwell, J. J.; McHardy, T.; Collins, I.; Bayliss, R. Molecular mechanisms of human IRE1 activation through dimerization and ligand binding. *Oncotarget* **2015**, *6*, 13019–13035.

- (7) Yoshida, H.; Matsui, T.; Yamamoto, A.; Okada, T.; Mori, K. XBP1 mRNA is induced by ATF6 and spliced by IRE1 in response to ER stress to produce a highly active transcription factor. *Cell* **2001**, *107*, 881–891.

- (8) Lee, A. H.; Iwakoshi, N. N.; Glimcher, L. H. XBP-1 regulates a subset of endoplasmic reticulum resident chaperone genes in the unfolded protein response. *Mol. Cell Biol.* **2003**, *23*, 7448–7459.

- (9) Hollien, J.; Weissman, J. S. Decay of endoplasmic reticulum-localized mRNAs during the unfolded protein response. *Science* **2006**, *313*, 104–107.

- (10) Urano, F.; Wang, X.; Bertolotti, A.; Zhang, Y.; Chung, P.; Harding, H. P.; Ron, D. Coupling of stress in the ER to activation of JNK protein kinases by transmembrane protein kinase IRE1. *Science* **2000**, *287*, 664–666.

- (11) Wang, M.; Kaufman, R. J. Protein misfolding in the endoplasmic reticulum as a conduit to human disease. *Nature* **2016**, *529*, 326–335.

- (12) Carrasco, D. R.; Sukhdeo, K.; Protopopova, M.; Sinha, R.; Enos, M.; Carrasco, D. E.; Zheng, M.; Mani, M.; Henderson, J.; Pinkus, G. S.; Munshi, N.; Horner, J.; Ivanova, E. V.; Protopopov, A.; Anderson, K. C.; Tonon, G.; DePinho, R. A. The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis. *Cancer Cell* **2007**, *11*, 349–360.

- (13) Chen, X.; Iliopoulos, D.; Zhang, Q.; Tang, Q.; Greenblatt, M. B.; Hatziapostolou, M.; Lim, E.; Tam, W. L.; Ni, M.; Chen, Y.; Mai, J.; Shen, H.; Hu, D. Z.; Adoro, S.; Hu, B.; Song, M.; Tan, C.; Landis, M. D.; Ferrari, M.; Shin, S. J.; Brown, M.; Chang, J. C.; Liu, X. S.; Glimcher, L. H. XBP1 promotes triple-negative breast cancer by controlling the HIF1 α pathway. *Nature* **2014**, *508*, 103–107.

- (14) Storm, M.; Sheng, X.; Arnoldussen, Y. J.; Saatcioglu, F. Prostate cancer and the unfolded protein response. *Oncotarget* **2016**, *7*, 54051–54066.

- (15) Cubillos-Ruiz, J. R.; Silberman, P. C.; Rutkowski, M. R.; Chopra, S.; Perales-Puchalt, A.; Song, M.; Zhang, S.; Bettigole, S. E.; Gupta, D.; Holcomb, K.; Ellenson, L. H.; Caputo, T.; Lee, A. H.; Conejo-Garcia, J. R.; Glimcher, L. H. ER stress sensor XBP1 controls anti-tumor immunity by disrupting dendritic cell homeostasis. *Cell* **2015**, *161*, 1527–1538.

- (16) Volkmann, K.; Lucas, J. L.; Vuga, D.; Wang, X.; Brumm, D.; Stiles, C.; Kriebel, D.; Der-Sarkissian, A.; Krishnan, K.; Schweitzer, C.; Liu, Z.; Malyankar, U. M.; Chiovitti, D.; Canny, M.; Durocher, D.; Sicheri, F.; Patterson, J. B. Potent and selective inhibitors of the inositol-requiring enzyme 1 endoribonuclease. *J. Biol. Chem.* **2011**, *286*, 12743–12755.

- (17) Cross, B. C.; Bond, P. J.; Sadowski, P. G.; Jha, B. K.; Zak, J.; Goodman, J. M.; Silverman, R. H.; Neubert, T. A.; Baxendale, I. R.; Ron, D.; Harding, H. P. The molecular basis for selective inhibition of unconventional mRNA splicing by an IRE1-binding small molecule. *Proc. Natl. Acad. Sci. U.S.A.* **2012**, *109*, E869–E878.

- (18) Ming, J.; Ruan, S.; Wang, M.; Ye, D.; Fan, N.; Meng, Q.; Tian, B.; Huang, T. A novel chemical, STF-083010, reverses tamoxifen-related drug resistance in breast cancer by inhibiting IRE1/XBP1. *Oncotarget* **2015**, *6*, 40692–40703.

- (19) Papanthou, I.; Denko, N. C.; Olson, M.; Van Melckebeke, H.; Lust, S.; Tam, A.; Solow-Cordero, D. E.; Bouley, D. M.; Offner, F.; Niwa, M.; Koong, A. C. Identification of an Ire1 α endonuclease

specific inhibitor with cytotoxic activity against human multiple myeloma. *Blood* **2011**, *117*, 1311–1314.

(20) Zhao, N.; Cao, J.; Xu, L.; Tang, Q.; Dobrolecki, L. E.; Lv, X.; Talukdar, M.; Lu, Y.; Wang, X.; Hu, D. Z.; Shi, Q.; Xiang, Y.; Wang, Y.; Liu, X.; Bu, W.; Jiang, Y.; Li, M.; Gong, Y.; Sun, Z.; Ying, H.; Yuan, B.; Lin, X.; Feng, X. H.; Hartig, S. M.; Li, F.; Shen, H.; Chen, Y.; Han, L.; Zeng, Q.; Patterson, J. B.; Kaiparettu, B. A.; Putluri, N.; Sicheri, F.; Rosen, J. M.; Lewis, M. T.; Chen, X. Pharmacological targeting of MYC-regulated IRE1/XBP1 pathway suppresses MYC-driven breast cancer. *J. Clin. Invest.* **2018**, *128*, 1283–1299.

(21) Wang, L.; Perera, B. G.; Hari, S. B.; Bhatarai, B.; Backes, B. J.; Seeliger, M. A.; Schürer, S. C.; Oakes, S. A.; Papa, F. R.; Maly, D. J. Divergent allosteric control of the IRE1 α endoribonuclease using kinase inhibitors. *Nat. Chem. Biol.* **2012**, *8*, 982–989.

(22) Concha, N. O.; Smallwood, A.; Bonnette, W.; Totoritis, R.; Zhang, G.; Federowicz, K.; Yang, J.; Qi, H.; Chen, S.; Campobasso, N.; Choudhry, A. E.; Shuster, L. E.; Evans, K. A.; Ralph, J.; Sweitzer, S.; Heerding, D. A.; Buser, C. A.; Su, D. S.; DeYoung, M. P. Long-range inhibitor-induced conformational regulation of human IRE1 α endoribonuclease activity. *Mol. Pharmacol.* **2015**, *88*, 1011–1023.

(23) Harrington, P. E.; Biswas, K.; Malwitz, D.; Tasker, A. S.; Mohr, C.; Andrews, K. L.; Dellamaggiore, K.; Kendall, R.; Beckmann, H.; Jaeckel, P.; Materna-Reichelt, S.; Allen, J. R.; Lipford, J. R. Unfolded protein response in cancer: IRE1 α inhibition by selective kinase ligands does not impair tumor cell viability. *ACS Med. Chem. Lett.* **2015**, *6*, 68–72.

(24) Feldman, H. C.; Tong, M.; Wang, L.; Meza-Acevedo, R.; Gobillot, T. A.; Lebedev, I.; Gliedt, M. J.; Hari, S. B.; Mitra, A. K.; Backes, B. J.; Papa, F. R.; Seeliger, M. A.; Maly, D. J. Structural and functional analysis of the allosteric inhibition of IRE1 α with ATP-competitive ligands. *ACS Chem. Biol.* **2016**, *11*, 2195–2205.

(25) Morita, S.; Villalta, S. A.; Feldman, H. C.; Register, A. C.; Rosenthal, W.; Hoffmann-Petersen, I. T.; Mehdizadeh, M.; Ghosh, R.; Wang, L.; Colon-Negron, K.; Meza-Acevedo, R.; Backes, B. J.; Maly, D. J.; Bluestone, J. A.; Papa, F. R. Targeting ABL-IRE1 α signaling spares ER-stressed pancreatic β cells to reverse autoimmune diabetes. *Cell Metab.* **2017**, *25*, 883–897.

(26) Vaccaro, W.; Chen, Z.; Dodd, D. S.; Huynh, T. N.; Lin, J.; Liu, C.; Mussari, C. P.; Tokarski, J. S.; Tortolani, D. R.; Wroblewski, S. T.; Lin, S. Preparation of Fused Heterocyclic Compounds Useful as Kinase Modulators. US20080045536, 2008.

(27) Clark, R. F.; Ba-Maung, N. Y.; Erickson, S. A.; Fidanze, S. D.; Mantei, R. A.; Sheppard, G. S.; Sorensen, B. K.; Wang, G. T.; Wang, J.; Bell, R. L. Preparation of Pyrimidine Inhibitors of Kinase Activity. International Application No. WO2010138575, 2010.

(28) Kusakabe, K.; Ide, N.; Daigo, Y.; Itoh, T.; Yamamoto, T.; Hashizume, H.; Nozu, K.; Yoshida, H.; Tadano, G.; Tagashira, S.; Higashino, K.; Okano, Y.; Sato, Y.; Inoue, M.; Iguchi, M.; Kanazawa, T.; Ishioka, Y.; Dohi, K.; Kido, Y.; Sakamoto, S.; Ando, S.; Maeda, M.; Higaki, M.; Baba, Y.; Nakamura, Y. Discovery of imidazo[1,2-b]pyridazine derivatives: selective and orally available Mps1 (TTK) kinase inhibitors exhibiting remarkable antiproliferative activity. *J. Med. Chem.* **2015**, *58*, 1760–1775.

(29) Uitdehaag, J. C. M.; de Man, J.; Willemsen-Seegers, N.; Prinsen, M. B. W.; Libouban, M. A. A.; Sterrenburg, J. G.; de Wit, J. J. P.; de Vetter, J. R. F.; de Roos, J. A. D. M.; Buijsman, R. C.; Zaman, G. J. R. Target residence time-guided optimization on TTK kinase results in inhibitors with potent anti-proliferative activity. *J. Mol. Biol.* **2017**, *429*, 2211–2230.

(30) Itzhak, D.; Bright, M.; McAndrew, P.; Mirza, A.; Newbatt, Y.; Strover, J.; Widya, M.; Thompson, A.; Morgan, G.; Collins, I.; Davies, F. Multiple autophosphorylations significantly enhance the endoribonuclease activity of human inositol requiring enzyme 1 α . *BMC Biochem.* **2014**, *15*, 3.

(31) Newbatt, Y.; Hardcastle, A.; McAndrew, P. C.; Strover, J. A.; Mirza, A.; Morgan, G. J.; Burke, R.; Davies, F. E.; Collins, I.; van Montfort, R. L. Identification of autophosphorylation inhibitors of the inositol-requiring enzyme 1 alpha (IRE1 α) by high-throughput screening using a DELFIA assay. *J. Biomol. Screen.* **2013**, *18*, 298–308.

(32) Potashman, M. H.; Bready, J.; Coxon, A.; DeMelfi, T. M., Jr.; DiPietro, L.; Doerr, N.; Elbaum, D.; Estrada, J.; Gallant, P.; Germain, J.; Gu, Y.; Harmange, J. C.; Kaufman, S. A.; Kendall, R.; Kim, J. L.; Kumar, G. N.; Long, A. M.; Neervannan, S.; Patel, V. F.; Polverino, A.; Rose, P.; van der Plas, S.; Whittington, D.; Zanon, R.; Zhao, H. Design, synthesis, and evaluation of orally active benzimidazoles and benzoxazoles as vascular endothelial growth factor-2 receptor tyrosine kinase inhibitors. *J. Med. Chem.* **2007**, *50*, 4351–4373.

(33) Liu, Y.; Gray, N. S. Rational design of inhibitors that bind to inactive kinase conformations. *Nat. Chem. Biol.* **2006**, *2*, 358–364.

(34) Iwawaki, T.; Hosoda, A.; Okuda, T.; Kamigori, Y.; Nomura-Furuwatari, C.; Kimata, Y.; Tsuru, A.; Kohno, K. Translational control by the ER transmembrane kinase/ribonuclease IRE1 under ER stress. *Nat. Cell Biol.* **2001**, *3*, 158–164.

(35) Dodson, C. A.; Kosmopoulou, M.; Richards, M. W.; Atrash, B.; Bavetsias, V.; Blagg, J.; Bayliss, R. Crystal structure of an Aurora-A mutant that mimics Aurora-B bound to MLN8054: insights into selectivity and drug design. *Biochem. J.* **2010**, *427*, 19–28; Erratum in: *Biochem. J.* **2010**, *427*, 551.

(36) Aliagas-Martin, I.; Burdick, D.; Corson, L.; Dotson, J.; Drummond, J.; Fields, C.; Huang, O. W.; Hunsaker, T.; Kleinheinz, T.; Krueger, E.; Liang, J.; Moffat, J.; Phillips, G.; Pulk, R.; Rawson, T. E.; Ultsch, M.; Walker, L.; Wiesmann, C.; Zhang, B.; Zhu, B. Y.; Cochran, A. G. A class of 2,4-bisanilinopyrimidine Aurora A inhibitors with unusually high selectivity against Aurora B. *J. Med. Chem.* **2009**, *52*, 3300–3307.

(37) Moslin, R.; Gardner, D.; Santella, J.; Zhang, Y.; Duncia, J. V.; Liu, C.; Lin, J.; Tokarski, J. S.; Strnad, J.; Pedicord, D.; Chen, J.; Blat, Y.; Zupa-Fernandez, A.; Cheng, L.; Sun, H.; Chaudhry, C.; Huang, C.; D'Arienzo, C.; Sack, J. S.; Muckelbauer, J. K.; Chang, C.; Tredup, J.; Xie, D.; Aranibar, N.; Burke, J. R.; Carter, P. H.; Weinstein, D. S. Identification of imidazo[1,2-b]pyridazine TYK2 pseudokinase ligands as potent and selective allosteric inhibitors of TYK2 signalling. *MedChemComm* **2017**, *8*, 700–712.

(38) Lucas, M. C.; Goldstein, D. M.; Hermann, J. C.; Kuglstatler, A.; Liu, W.; Luk, K. C.; Padilla, F.; Slade, M.; Villasenor, A. G.; Wanner, J.; Xie, W.; Zhang, X.; Liao, C. Rational design of highly selective spleen tyrosine kinase inhibitors. *J. Med. Chem.* **2012**, *55*, 10414–10423.

(39) Smith, C. R.; Dougan, D. R.; Komandla, M.; Kanouni, T.; Knight, B.; Lawson, J. D.; Sabat, M.; Taylor, E. R.; Vu, P.; Wyrick, C. Fragment-based discovery of a small molecule inhibitor of Bruton's tyrosine kinase. *J. Med. Chem.* **2015**, *58*, 5437–5444.

(40) Miller, R. M.; Paavilainen, V. O.; Krishnan, S.; Serafimova, I. M.; Taunton, J. Electrophilic fragment-based design of reversible covalent kinase inhibitors. *J. Am. Chem. Soc.* **2013**, *135*, 5298–5301.

(41) Li, H.; Korennykh, A. V.; Behrman, S. L.; Walter, P. Mammalian endoplasmic reticulum stress sensor IRE1 signals by dynamic clustering. *Proc. Natl. Acad. Sci. U.S.A.* **2010**, *107*, 16113–16118.

(42) Bayliss, R.; Haq, T.; Yeoh, S. The Ys and wherefores of protein kinase autoinhibition. *Biochim. Biophys. Acta* **2015**, *1854*, 1586–1594.

(43) Lavoie, H.; Li, J. J.; Thevakumaran, N.; Therrien, M.; Sicheri, F. Dimerization-induced allostery in protein kinase regulation. *Trends Biochem. Sci.* **2014**, *39*, 475–486.

(44) Hatzivassiliou, G.; Song, K.; Yen, I.; Brandhuber, B. J.; Anderson, D. J.; Alvarado, R.; Ludlam, M. J.; Stokoe, D.; Gloor, S. L.; Vigers, G.; Morales, T.; Aliagas, I.; Liu, B.; Sideris, S.; Hoefflich, K. P.; Jaiswal, B. S.; Seshagiri, S.; Koeppen, H.; Belvin, M.; Friedman, L. S.; Malek, S. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. *Nature* **2010**, *464*, 431–435.

(45) Poulidakos, P. I.; Zhang, C.; Bollag, G.; Shokat, K. M.; Rosen, N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. *Nature* **2010**, *464*, 427–430.

(46) Arora, R.; Di Michele, M.; Stes, E.; Vandermarliere, E.; Martens, L.; Gevaert, K.; Van Heerde, E.; Linders, J. T.; Brehmer, D.; Jacoby, E.; Bonnet, P. Structural investigation of B-Raf paradox breaker and inducer inhibitors. *J. Med. Chem.* **2015**, *58*, 1818–1831.

(47) Byrne, D. P.; Foulkes, D. M.; Eyers, P. A. Pseudokinases: update on their functions and evaluation as new drug targets. *Future Med. Chem.* **2017**, *9*, 245–265.

(48) Song, M.; Sandoval, T. A.; Chae, C. S.; Chopra, S.; Tan, C.; Rutkowski, M. R.; Raundhal, M.; Chaurio, R. A.; Payne, K. K.; Konrad, C.; Bettigole, S. E.; Shin, H. R.; Crowley, M. J. P.; Cerliani, J. P.; Kossenkov, A. V.; Motorykin, I.; Zhang, S.; Manfredi, G.; Zamarin, D.; Holcomb, K.; Rodriguez, P. C.; Rabinovich, G. A.; Conejo-Garcia, J. R.; Glimcher, L. H.; Cubillos-Ruiz, J. R. IRE1 α -XBP1 controls T cell function in ovarian cancer by regulating mitochondrial activity. *Nature* **2018**, *562*, 423–428.

(49) Kabsch, W. XDS. *Acta Crystallogr., Sect. D: Biol. Crystallogr.* **2010**, *66*, 125–132.

(50) Winn, M. D.; Ballard, C. C.; Cowtan, K. D.; Dodson, E. J.; Emsley, P.; Evans, P. R.; Keegan, R. M.; Krissinel, E. B.; Leslie, A. G.; McCoy, A.; McNicholas, S. J.; Murshudov, G. N.; Pannu, N. S.; Potterton, E. A.; Powell, H. R.; Read, R. J.; Vagin, A.; Wilson, K. S. Overview of the CCP4 suite and current developments. *Acta Crystallogr., Sect. D: Biol. Crystallogr.* **2011**, *67*, 235–242.

(51) Emsley, P.; Lohkamp, B.; Scott, W. G.; Cowtan, K. Features and development of Coot. *Acta Crystallogr., Sect. D: Biol. Crystallogr.* **2010**, *66*, 486–501.

(52) Murshudov, G. N.; Vagin, A. A.; Dodson, E. J. Refinement of macromolecular structures by the maximum-likelihood method. *Acta Crystallogr., Sect. D: Biol. Crystallogr.* **1997**, *53*, 240–255.

(53) *Maestro*, version 9.3; Schrödinger, LLC: New York, 2012.

(54) *Glide*, version 5.8; Schrödinger, LLC: New York, 2012.

(55) *LigPrep*, version 2.5; Schrödinger, LLC: New York, 2011.

(56) Zhegalova, N. G.; Gonzales, G.; Berezin, M. Y. Synthesis of nitric oxide probes with fluorescence lifetime sensitivity. *Org. Biomol. Chem.* **2013**, *11*, 8228–8234.